<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nanomaterials (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Nanomaterials (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">3130</journal-id><journal-id journal-id-type="pmc-domain">nanomat</journal-id><journal-id journal-id-type="publisher-id">nanomaterials</journal-id><journal-title-group><journal-title>Nanomaterials</journal-title></journal-title-group><issn pub-type="epub">2079-4991</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12430098</article-id><article-id pub-id-type="pmcid-ver">PMC12430098.1</article-id><article-id pub-id-type="pmcaid">12430098</article-id><article-id pub-id-type="pmcaiid">12430098</article-id><article-id pub-id-type="pmid">40938004</article-id><article-id pub-id-type="doi">10.3390/nano15171326</article-id><article-id pub-id-type="publisher-id">nanomaterials-15-01326</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Lipid-Based Drug Delivery Systems: Concepts and Recent Advances in Transdermal Applications</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Antonara</surname><given-names initials="L">Lefkothea</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Triantafyllopoulou</surname><given-names initials="E">Efstathia</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chountoulesi</surname><given-names initials="M">Maria</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1197-9010</contrib-id><name name-style="western"><surname>Pippa</surname><given-names initials="N">Natassa</given-names></name><xref rid="c1-nanomaterials-15-01326" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7263-0795</contrib-id><name name-style="western"><surname>Dallas</surname><given-names initials="PP">Paraskevas P.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rekkas</surname><given-names initials="DM">Dimitrios M.</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Alfei</surname><given-names initials="S">Silvana</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Zuccari</surname><given-names initials="G">Guendalina</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-nanomaterials-15-01326">Section of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece; <email>lefkanto@pharm.uoa.gr</email> (L.A.); <email>efstrian@pharm.uoa.gr</email> (E.T.); <email>mchountoules@pharm.uoa.gr</email> (M.C.); <email>dallas@pharm.uoa.gr</email> (P.P.D.); <email>rekkas@pharm.uoa.gr</email> (D.M.R.)</aff><author-notes><corresp id="c1-nanomaterials-15-01326"><label>*</label>Correspondence: <email>natpippa@pharm.uoa.gr</email>; Tel.: +30-210-7274025</corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>15</volume><issue>17</issue><issue-id pub-id-type="pmc-issue-id">496802</issue-id><elocation-id>1326</elocation-id><history><date date-type="received"><day>24</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>28</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 11:25:14.803"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nanomaterials-15-01326.pdf"/><abstract><p>Lipid-based nanocarriers are ideal drug delivery systems for transdermal administration due to their biocompatibility and biodegradability. Their lipophilicity and/or similarity to the natural lipids of the epidermis enable intermolecular interactions with the lipid membrane and therefore result in effective passage through the skin. The purpose of this review is to focus on lipid-based drug delivery nanoplatforms administered via the transdermal route by summarizing the most recent developments with the intention of fast clinical translation. Liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), ethosomes, and transfersomes exhibit ideal physicochemical characteristics and encapsulation efficiency to enhance the effectiveness of the incorporated Active Pharmaceutical Ingredients (APIs). The state of the art for fabricating transcutaneous lipid drug delivery nanoparticles and the strategies for overcoming the current obstacles, as well as the added value of novel formulations, will be discussed within the scope of Quality by Design applications. The limitations and challenges that still exist will also be considered.</p></abstract><kwd-group><kwd>lipid nanoparticles</kwd><kwd>transdermal</kwd><kwd>drug delivery nanosystems</kwd><kwd>skin administration</kwd><kwd>liposomes</kwd><kwd>ethosomes</kwd><kwd>nanostructured lipid carriers</kwd><kwd>Quality by Design</kwd><kwd>solid lipid nanoparticles</kwd><kwd>transferosomes</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-nanomaterials-15-01326"><title>1. Introduction</title><p>The transdermal route is favorable for drug administration, especially due to its non-invasive character. Other benefits include its controlled release capability, the avoidance of presystemic metabolism (first-pass effect), and the reduction in side effects [<xref rid="B1-nanomaterials-15-01326" ref-type="bibr">1</xref>,<xref rid="B2-nanomaterials-15-01326" ref-type="bibr">2</xref>]. However, it is not often selected due to the limitations that still exist. Among other functionalities, skin is a physiological barrier, being impervious to some compounds and thus limiting drug permeation, while it seems that there is also skin-mediated metabolism. Bearing in mind that skin is a dynamic system, the degree of a drug&#8217;s penetration is dependent on skin condition and hydration as well [<xref rid="B1-nanomaterials-15-01326" ref-type="bibr">1</xref>,<xref rid="B2-nanomaterials-15-01326" ref-type="bibr">2</xref>]. Additionally, Active Pharmaceutical Ingredients (APIs) that are ionizable molecules and/or have a molecular weight over 500 Dalton face difficulties permeating the skin [<xref rid="B3-nanomaterials-15-01326" ref-type="bibr">3</xref>]. Even in the case of APIs that could penetrate the stratum corneum successfully, passing through the skin multilayer can be a slow process, leading to ineffective therapeutic drug levels [<xref rid="B2-nanomaterials-15-01326" ref-type="bibr">2</xref>]. Strategies to exceed such barriers involve physical and chemical methods. Ionto-, sono-, thermo-, and magnetophoresis; electroporation; microneedles; and microdermabrasion are the existing physical methodologies, whereas chemical techniques include the usage of prodrugs or excipients that enhance skin permeation, such as terpenes, alcohols, glycols, etc. [<xref rid="B4-nanomaterials-15-01326" ref-type="bibr">4</xref>,<xref rid="B5-nanomaterials-15-01326" ref-type="bibr">5</xref>,<xref rid="B6-nanomaterials-15-01326" ref-type="bibr">6</xref>,<xref rid="B7-nanomaterials-15-01326" ref-type="bibr">7</xref>]. Both approaches show several disadvantages including irritation and other side effects [<xref rid="B4-nanomaterials-15-01326" ref-type="bibr">4</xref>]. Alternatively, the use of novel formulations utilizing nanoparticulate systems as drug delivery platforms is a promising strategy for transcutaneous administration.</p><p>Nano-drug delivery systems are innovative carriers comprising a broad spectrum of natural and/or chemical materials, such as inorganic, organic, or both. Their common feature&#8212;and main advantage&#8212;is their size, as being on the nanoscale results in them having an increased surface area [<xref rid="B8-nanomaterials-15-01326" ref-type="bibr">8</xref>]. They can be tailor-made according to the needs of their intended use and utilized for the encapsulation of either APIs with low molecular weight or macromolecules. In addition, they have the capability of being able to safeguard their load from degradation, promote their modified release, and improve their pharmacokinetics. Their flexibility permits the incorporation of both hydrophilic and hydrophobic APIs and the co-loading of more than one compound with no compatibility issues, and they have excellent surface functionalization and stimuli-responsive capability. Apart from drug delivery, they can be utilized for imaging and theragnostic purposes as well. Therefore, they are identified as a smart multifunctional drug delivery system, and they are selected to safely, effectively, and selectively deliver their cargo [<xref rid="B8-nanomaterials-15-01326" ref-type="bibr">8</xref>,<xref rid="B9-nanomaterials-15-01326" ref-type="bibr">9</xref>,<xref rid="B10-nanomaterials-15-01326" ref-type="bibr">10</xref>]. However, there are still important considerations, especially regarding their safety due to their nanoparticulate nature as well as difficulties in their clinical translation due to heterogeneity in populations and the clinical gap between studies of humans and animals [<xref rid="B8-nanomaterials-15-01326" ref-type="bibr">8</xref>,<xref rid="B11-nanomaterials-15-01326" ref-type="bibr">11</xref>]. Referring to transdermal administration, the different categories of nanoparticles that can be found in the literature are organic ones, including lipid and polymer-based nanosystems; inorganic ones, such as metallic (gold nanoparticles, etc.); and carbon nanostructures and nanogels (or nanoemulsions) [<xref rid="B12-nanomaterials-15-01326" ref-type="bibr">12</xref>,<xref rid="B13-nanomaterials-15-01326" ref-type="bibr">13</xref>]. Among the most popular nanovectors are lipid drug delivery systems due to their advantages that are going to be discussed in detail.</p><p>The purpose of this review is to focus on lipid-based drug delivery nanoplatforms administrated via the transdermal route by summarizing the most recent developments with the intention of fast clinical translation. More specifically, the systems will be analyzed in pharmaceutical technology terms by describing the different types of lipid-based drug delivery systems for transdermal administration, as well as the Quality by Design approach applied during the development of lipid-based transdermal products, for the rational design of their formulation and manufacturing process. The state of the art for fabricating transcutaneous lipid drug delivery nanoparticles and the strategies for overcoming the current obstacles, as well as the added value of novel formulations, will be discussed thoroughly. Last but not least, case studies found in the literature about pre- and clinical studies on these systems will be referenced, while the current status and some considerations of their regulatory framework will also be described. The limitations and challenges that still exist will also be considered. The research methodology in this review work included a search conducted in the electronic databases &#8220;PubMed&#8221; and &#8220;Google Scholar&#8221; for articles published within the last 10 years, from 2015 to 2025. The search terms were the English words &#8220;transdermal administration&#8221; AND &#8220;lipid-based nanoparticles&#8221;, along with specific keywords, such as &#8220;liposomes&#8221;, &#8220;ethosomes&#8221;, &#8220;SLNs&#8221;, &#8220;NLC&#8221;, and &#8220;transferosomes&#8221;.</p></sec><sec id="sec2-nanomaterials-15-01326"><title>2. Anatomy of the Skin: Challenges for Formulation Strategies</title><p>The skin represents the largest organ of the human body, accounting for approximately 10% of total body mass in an average individual. It acts as a protective barrier between the body and the outside world, shielding against harmful ultraviolet (UV) radiation, chemicals, allergens, and microorganisms, while also preventing the loss of water and essential nutrients. In addition to its protective function, the skin plays a key role in regulating body temperature and blood pressure, helping to maintain internal balance. It also serves as a sensory organ, detecting and responding to external stimuli such as touch, pressure, pain, and temperature [<xref rid="B14-nanomaterials-15-01326" ref-type="bibr">14</xref>] (<xref rid="nanomaterials-15-01326-f001" ref-type="fig">Figure 1</xref>).</p><p>Human skin is composed of four primary layers, arranged from the outermost to the innermost layer, i.e., the stratum corneum, the viable epidermis, the dermis, and subcutaneous tissues. Embedded within these layers are various appendages such as hair follicles and sweat glands, which are visible on the skin&#8217;s surface. The stratum corneum consists of the outermost surface of the skin, with a thickness of 10&#8211;20 &#956;m, functioning as the primary barrier of the skin. This layer is responsible for the regulation of the water loss and the prevention of the permeation of potentially harmful substances and microorganisms from the skin surface. Structurally, the stratum corneum is often compared to a brick wall, where the corneocytes function as the &#8220;bricks&#8221; and the surrounding lamellar lipids act as the &#8220;mortar&#8221; [<xref rid="B14-nanomaterials-15-01326" ref-type="bibr">14</xref>]. Corneocytes are flattened dead cells that have lost their nuclei as a result of keratinization, and they mainly consist of keratin (at a percentage of 70&#8211;80%) and a natural moisturizing factor. Their high water content allows them to swell, which helps maintain the elasticity of the stratum corneum and prevents the development of cracks in the skin [<xref rid="B16-nanomaterials-15-01326" ref-type="bibr">16</xref>].</p><p>The viable epidermis is a multilayered region whose thickness varies depending on the anatomical site. It consists of four different layers, i.e., stratum lucidum (encountered in areas with thick skin), stratum granulosum, stratum spinosum, and stratum basale. Keratinocytes are the main cell population, while melanocytes, Langerhans cells, and Merkel cells can be encountered at smaller percentages [<xref rid="B16-nanomaterials-15-01326" ref-type="bibr">16</xref>]. Melanocytes are responsible for the skin&#8217;s pigmentation by producing melanin, a high-molecular-weight polymer whose primary function is the protection of the skin from the effects of harmful UV radiation. Langerhans cells are a part of the immune system with the main function of protecting the skin from antigens by sensitizing T cells in the regional lymph nodes. Finally, Merkel cells are involved in sensation, as they are associated with nerve endings.</p><p>The dermis is a layer of 2&#8211;5 mm thickness connecting the epidermis and the subcutaneous tissue. Its extensive network of collagen fibrils provides support, while the dense elastic connective tissue provides elasticity and flexibility to the skin. Due to its hydrophilic structure, the dermis is not considered an effective barrier to the permeation of most drugs, apart from the ones that are highly lipophilic. In this region of the skin, several structures and appendages can be encountered, such as blood and lymph vessels, nerve endings, hair follicles, and sebaceous and sweat glands. Finally, the subcutaneous tissue is a lipid layer acting as a heat insulator as well as protecting against mechanical pressure. It also functions as energy storage, which can be available when necessary [<xref rid="B14-nanomaterials-15-01326" ref-type="bibr">14</xref>].</p></sec><sec id="sec3-nanomaterials-15-01326"><title>3. Lipid-Based Systems as a Strategy for Permeation Enhancement</title><p>As already stated in the previous section, the barrier function of the stratum corneum is crucial for the prevention of extensive water loss from the body and subsequently the protection of life. However, this exact barrier formation is also responsible for the limited drug permeation, which leads to difficulty in achieving sufficient therapeutic dosages systemically. As a result, various methods of permeation enhancement have been developed through the years and are categorized as passive and active [<xref rid="B17-nanomaterials-15-01326" ref-type="bibr">17</xref>]. While active techniques implement the application of a physical force for the breakage of the stratum corneum&#8217;s structure, passive ones are based on the utilization of chemical compounds such as ionic pairs, eutectic mixtures, chemical enhancers, and lipid-based systems, with the latter gaining an increasing interest in recent decades.</p><p>Lipids are a wide category favoring the formation of different types of drug delivery systems with versatile properties, amphiphilicity, and different mechanisms to permeate the skin. Moreover, they could protect their cargo from different environmental conditions ameliorating its stability [<xref rid="B2-nanomaterials-15-01326" ref-type="bibr">2</xref>,<xref rid="B6-nanomaterials-15-01326" ref-type="bibr">6</xref>]. Therefore, they can incorporate APIs with challenging properties and/or sensitive molecules with high molecular weight (such as nucleic acids and proteins) [<xref rid="B12-nanomaterials-15-01326" ref-type="bibr">12</xref>]. Optimizing their physicochemical features or modifying their surface are efficient strategies for passive or active targeting and thus increased potency in the intended area with minimum side effects [<xref rid="B4-nanomaterials-15-01326" ref-type="bibr">4</xref>]. In this manner, they could improve skin permeation and enhance the passive transdermal absorption of APIs with non-ideal properties for this route of administration, such as antibiotics, etc. [<xref rid="B1-nanomaterials-15-01326" ref-type="bibr">1</xref>,<xref rid="B18-nanomaterials-15-01326" ref-type="bibr">18</xref>]. They could be suitable candidates for novel therapies as well. For example, they might be selected to deliver adjuvants for transdermal vaccination or to ameliorate the transcutaneous delivery of macromolecules [<xref rid="B7-nanomaterials-15-01326" ref-type="bibr">7</xref>,<xref rid="B19-nanomaterials-15-01326" ref-type="bibr">19</xref>].</p><p>Lipid-based drug delivery systems are nanoparticle-sized experimental models of biomembranes, which are extensively used as vehicles for the controlled, targeted, or non-targeted delivery of active compounds via topical or systemic routes [<xref rid="B20-nanomaterials-15-01326" ref-type="bibr">20</xref>]. They exhibit a series of advantages such as biocompatibility, improved physicochemical stabilization, and non-toxicity with the ability to incorporate both hydrophilic and hydrophobic active substances [<xref rid="B21-nanomaterials-15-01326" ref-type="bibr">21</xref>]. Although they have been extensively utilized as a means of drug permeation, their mechanism of action is not yet fully clarified. Research studies indicate four potential mechanisms of permeation enhancement, i.e., (I) intact transport of the loaded molecules through the various layers of the skin, (II) functioning as permeation enhancers by liquefaction of the stratum corneum membrane, (III) exchange of the active substance during the fusion of the lipid bilayer with the surface of the skin&#8217;s cells, and/or (IV) absorption form the skin appendages such as hair follicles and sweat glands. In general, the mechanism(s) taking place are mostly dependent on the composition and the size of the particles. Specifically, particles of sizes less than 300 nm achieve a release of their content to some degree at the deepest skin layers, with maximum values achieved at particle sizes of less than or equal to 70 nm [<xref rid="B22-nanomaterials-15-01326" ref-type="bibr">22</xref>].</p><p>A comparative analysis of the lipid-based drug delivery systems highlights significant differences in their skin permeation mechanisms. Specifically, liposomes, composed mainly of phospholipids, remain located at the upper skin layers with little permeation into the deepest layers. Imaging studies such as confocal laser scanning microscopy (CLSM) [<xref rid="B23-nanomaterials-15-01326" ref-type="bibr">23</xref>,<xref rid="B24-nanomaterials-15-01326" ref-type="bibr">24</xref>] and in vitro tape stripping confirm their restricted diffusion profile [<xref rid="B25-nanomaterials-15-01326" ref-type="bibr">25</xref>]. On the contrary, transfersomes, which include edge activators to enhance vesicle deformability, can penetrate more effectively through the intercellular lipid matrix of the stratum corneum by changing their shape to pass through the narrow channels. This mechanism is supported by ex vivo skin permeation studies and CLSM [<xref rid="B26-nanomaterials-15-01326" ref-type="bibr">26</xref>,<xref rid="B27-nanomaterials-15-01326" ref-type="bibr">27</xref>]. However, their penetration depth is yet more limited in comparison to ethosomes, probably due to their larger size.</p><p>Ethosomes, another advanced vesicular system containing high concentrations of ethanol, facilitate deep skin penetration by fluidizing the SC lipids and enhancing the flexibility of the vesicle membrane. CLSM, transmission electron microscope (TEM), and Raman spectroscopy have provided strong visual evidence of their enhanced skin permeation compared to conventional forms [<xref rid="B28-nanomaterials-15-01326" ref-type="bibr">28</xref>,<xref rid="B29-nanomaterials-15-01326" ref-type="bibr">29</xref>].</p><p>Lipid-drug delivery systems such as solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) offer alternative strategies for dermal delivery. SLNs, consisting entirely of solid lipids, form an occlusive layer on the skin surface that enhances hydration and provides a slow-release profile, while NLCs&#8212;comprising a mixture of solid and liquid lipids&#8212;create a less-ordered lipid matrix that allows for improved drug loading and a more flexible structure. These findings are supported by ex vivo permeation models [<xref rid="B30-nanomaterials-15-01326" ref-type="bibr">30</xref>,<xref rid="B31-nanomaterials-15-01326" ref-type="bibr">31</xref>] and CLSM [<xref rid="B32-nanomaterials-15-01326" ref-type="bibr">32</xref>] imaging results. Overall, in the case where penetration at the deeper skin layers is desired, transfersomes, ethosomes, and NLCs constitute the most promising choices.</p></sec><sec id="sec4-nanomaterials-15-01326"><title>4. Types of Lipid-Based Drug Delivery Systems for Transdermal Administration</title><p>As already stated, the lipid-based systems can be divided into a number of categories based on their composition. Specifically, liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), ethosomes, transfersomes, niosomes, cubosomes, archaesomes, invasomes, penetration enhancer-containing vesicles (PEVs), and several other types of lipid-based systems have been encountered in topical and transdermal formulations applied on the skin&#8217;s surface throughout the literature. Among these systems, the first six categories are the most frequently encountered and chosen to be described in more detail [<xref rid="B20-nanomaterials-15-01326" ref-type="bibr">20</xref>]. A synopsis of the following examples, encompassing the characteristics of the nanostructures, the incorporated Active Pharmaceutical Ingredients (APIs), and the principal results, is presented in <xref rid="nanomaterials-15-01326-t001" ref-type="table">Table 1</xref>.</p><sec id="sec4dot1-nanomaterials-15-01326"><title>4.1. Liposomes</title><p>Liposomes are mono- or multi-lipid bilayer spherical structures with an aqueous core, consisting primarily of phospholipids and cholesterol. They are suitable for the incorporation of both hydrophilic and lipophilic drugs, either at their aqueous interior center or within the lipid bilayers. These types of nanocarriers exhibit a series of advantages, such as improved drug permeation with a prolonged-release profile and thus reduced side effects. Their site of action (topical or transdermal) can be determined via their particle size, finding numerous applications throughout the literature. Some examples of drugs incorporated are progesterone, topical anesthetics such as benzocaine, lidocaine, and tetracaine, betamethasone dipropionate, retinoids, etc. for the treatment of psoriasis [<xref rid="B56-nanomaterials-15-01326" ref-type="bibr">56</xref>]. Liposomes can also be utilized for the delivery of peptides such as cyclosporine A or for regenerative purposes to heal wounds.</p><p>Paclitaxel-loaded liposomes have been investigated as a potential therapeutic strategy for the treatment of squamous cell carcinoma. Findings from this study suggest that, compared to the administration of free paclitaxel, the liposomal formulation enhances drug penetration through the stratum corneum and increases antiproliferative activity, offering a promising approach for improving the management of squamous cell carcinoma [<xref rid="B15-nanomaterials-15-01326" ref-type="bibr">15</xref>]. In another study [<xref rid="B57-nanomaterials-15-01326" ref-type="bibr">57</xref>,<xref rid="B58-nanomaterials-15-01326" ref-type="bibr">58</xref>], a liposomal system incorporating DNA repair enzymes was evaluated for its efficacy in treating skin cancer. Specifically, the formulation contained T4 endonuclease V, a DNA repair enzyme derived from bacteriophage T4, which is capable of substituting the UV-damaged repair enzymes in human cells and initiating excision repair. In vitro experiments demonstrated that intracellular delivery of T4 endonuclease V successfully corrected DNA repair deficiencies. Clinical treatment of DNA repair-deficient skin conditions was performed using a T4N5 liposomal lotion, which showed enhanced removal of UV-induced DNA lesions within the first few hours post-application.</p><p>Hosny and Aldawsari developed avanafil, a phosphodiesterase-5 enzyme inhibitor used for the erectile dysfunction treatment, which was incorporated in a liposomal form in terms of enhancing its permeability. The results of the ex vivo permeation studies demonstrated that the developed liposomal distributions achieved a 4-fold increase in permeation compared to the conventional suspensions, while bioavailability was even up to 7 times higher [<xref rid="B33-nanomaterials-15-01326" ref-type="bibr">33</xref>]. Vitamin D3 and folic acid have also been investigated in liposomal formulations as UV-protective, antiaging, and regenerative agents, with promising results when compared with traditional ones [<xref rid="B34-nanomaterials-15-01326" ref-type="bibr">34</xref>,<xref rid="B35-nanomaterials-15-01326" ref-type="bibr">35</xref>].</p><p>Finally, pain management is considered one of the most critical medical issues; thus, the incorporation of non-anti-inflammatory agents in liposomes is still under investigation. Specifically, Franze et al. developed a lidocaine/CBD (cannabidiol) liposomal delivery system, where an increase in skin permeability was achieved allowing the release of the drug combination to the deeper skin layers. The aforementioned formulation is proved to be stable in long-term storage conditions for approximately one year, paving the way for new research in the field of pain control [<xref rid="B36-nanomaterials-15-01326" ref-type="bibr">36</xref>].</p></sec><sec id="sec4dot2-nanomaterials-15-01326"><title>4.2. Solid Lipid Nanoparticles (SLNs)</title><p>Solid lipid nanoparticles or SLNs are prepared by lipids that are solid at body temperature and consequently at room temperature stabilized by surfactants (<xref rid="nanomaterials-15-01326-f002" ref-type="fig">Figure 2</xref>). Their size ranges from 50 to 2000 nm, exhibiting biodegradability, low toxicity, biocompatibility, and enhanced physical stability in comparison to the conventional liposomes. The active substance can be incorporated either in a dissolved or a dispersed state while SLNs are also considered promising carriers especially for lipophilic drugs (logP &gt; 3) with molecular weights of above 500 Daltons. The system as a whole has the potential of forming an occlusive lipid film on the surface of the skin, prolonging the residence on the area and enhancing the release to the skin. This phenomenon is even more intense in anatomical areas where skin appendages are encountered [<xref rid="B15-nanomaterials-15-01326" ref-type="bibr">15</xref>].</p><p>Several key factors influence the drug loading capacity, release profile, and stability of lipid-based nanoparticles, including the polymorphic form of the lipid core and the length of the lipid chains. The presence of alkyl chains in the lipids exhibit a diverse range of packing arrangements such as &#945;, &#946;&#8217;, and &#946; forms. These different packings ultimately influence the amount of loaded drug, stability profile, and drug release. For example, the presence of caprylic/capric triglyceride in the lipid core enhances physical stability by delaying recrystallization of the lipids. The degree of crystallinity can be assessed using X-ray diffraction (XRD), a widely employed technique for characterizing the crystalline structure of solid materials. Lipid composition also plays a critical role; highly crystalline lipids with well-ordered lattices tend to expel the drug, whereas more complex lipids&#8212;such as glycerol dibehenate, glyceryl monostearate, and glyceryl palmitostearate&#8212;composed of mono-, di-, and triglycerides, form imperfect lattices that allow for greater drug incorporation due to disrupted molecular packing [<xref rid="B59-nanomaterials-15-01326" ref-type="bibr">59</xref>,<xref rid="B60-nanomaterials-15-01326" ref-type="bibr">60</xref>].</p><p>Lipid nanoparticles are typically prepared by dissolving or dispersing the active compound within the lipid matrix, followed by the application of high energy to form nanostructures. In most of the techniques applied to large-scale batches, the drug is incorporated either in the melted lipid phase or in the solution of the lipid with organic solvents. In the first case, methods such as hot and cold high-shear homogenization and ultrasonication are included, while in the second one, solvent emulsification/evaporation, double emulsification, solvent diffusion, and solvent displacement find application [<xref rid="B60-nanomaterials-15-01326" ref-type="bibr">60</xref>]. Lately, the techniques of nanospray drying and hot melt extrusion are of great concern for scale-up and commercial continuous productions, as the nanoparticles are produced in a single step.</p><p>Regarding its in vivo efficacy, studies performed with cyclosporine A and calcipotriol-loaded lipid NPs demonstrated the lowest scores of eye inflammation and psoriatic symptoms in relation to the results collected from free medicines. Loteprednol etabonate (LE), a carbon-ester corticosteroid utilized for the treatment of inflammation, exhibited reduced adverse effects when incorporated in SLNs, while an increase in its action was achieved even at lower loading and dosage frequency [<xref rid="B15-nanomaterials-15-01326" ref-type="bibr">15</xref>]. Metformin, a known anti-diabetic agent, was loaded in solid lipid nanocarriers made of Tween 60, cholesterol, Span 60, and beeswax and evaluated in terms of efficacy and stability. This formulated carrier can increase the skin penetration with higher concentrations at the deeper layers of the skin, while regarding its stability; an optimization study is to be carried out to optimize the portions of the constituents [<xref rid="B37-nanomaterials-15-01326" ref-type="bibr">37</xref>]. Antifungal compounds such as amphotericin B [<xref rid="B38-nanomaterials-15-01326" ref-type="bibr">38</xref>], eugenol [<xref rid="B39-nanomaterials-15-01326" ref-type="bibr">39</xref>], fluconazole, griseofulvin [<xref rid="B61-nanomaterials-15-01326" ref-type="bibr">61</xref>], and miconazole nitrate [<xref rid="B62-nanomaterials-15-01326" ref-type="bibr">62</xref>] have been also incorporated in nanocarriers with promising results in terms of efficacy and adverse effects. SLNs also find many applications in the cosmeceutical field. Specifically, antioxidant molecules such as sesamol [<xref rid="B40-nanomaterials-15-01326" ref-type="bibr">40</xref>], silybin [<xref rid="B41-nanomaterials-15-01326" ref-type="bibr">41</xref>], and idebenone [<xref rid="B63-nanomaterials-15-01326" ref-type="bibr">63</xref>]; anti-wrinkle agents such as retinyl palmitate [<xref rid="B64-nanomaterials-15-01326" ref-type="bibr">64</xref>]; and many others have been developed in solid lipid nanocarriers with promising results. Benzoyl peroxide SLNs have significant advantages relative to commercial formulations, such as higher drug accumulation and reduced side effects and inflammation [<xref rid="B15-nanomaterials-15-01326" ref-type="bibr">15</xref>].</p></sec><sec id="sec4dot3-nanomaterials-15-01326"><title>4.3. Nanostructured Lipid Carriers (NLCs)</title><p>Nanostructured lipid carriers (NLCs) are a form of nanocarriers that resemble the solid lipid ones mentioned earlier and have been developed to address the crystallinity issues and limitations that are related to the SLNs. For this reason, their core is formed from the combination of solid and liquid lipids, with some of the most common liquid lipids used for their preparation being oleic acid, sesame oil, almond oil, mixtures of medium-chain triglycerides, and many others. Compared to the remaining types of nanocarriers, they exhibit numerous benefits such as drug safety, controlled release of drugs, and enhanced bioavailability by increasing permeation either through the surface of the skin or its appendages. Specifically, NLCs interfere with the lipid bilayers causing lipid reorganization in the stratum corneum, thereby enhancing drug penetration. They also recover skin hydration by stopping transepidermal water loss and through film formation on the stratum corneum&#8217;s surface [<xref rid="B42-nanomaterials-15-01326" ref-type="bibr">42</xref>].</p><p>There are three main types of nanostructured lipid carriers: (I) Type 1 (imperfect) which acquires an imperfect crystal core structure due to the substitution of a portion of the solid lipids with liquid ones, and it is characterized by high drug loading and release properties, (II) Type 2 (amorphous) which contains medium-chain triglycerides as liquid lipids to maintain an &#945;-polymorphic state after solidification, avoiding in this manner any crystallinity-related issues, and (III) Type 3 (multiple) in which small-sized oil droplets are dispersed in the solid lipid matrix resembling the structure of w/o/w emulsions and exhibiting enhanced drug loading and stability (<xref rid="nanomaterials-15-01326-f003" ref-type="fig">Figure 3</xref>).</p><p>NLCs can be prepared by a variety of methods such as (a) high-pressure homogenization where the excipients are forced to pass through a micro-sized nozzle under high pressure, (b) high-shear homogenization and ultasonication where the contents of the lipid core are heated up to their melting point, mixed under high speeds with the aqueous phase to form an emulsion, and then ultrasonicated to reduce the particle size, (c) microemulsion technique where a microemulsion is initially prepared at high melting temperatures and then cooled down rapidly to form the NLCs, and (d) solvent emulsification/evaporation where lipids are dissolved in an organic solvent and then emulsified to the aqueous phase while evaporated to retrieve the precipitated particles [<xref rid="B42-nanomaterials-15-01326" ref-type="bibr">42</xref>].</p><p>NLCs find numerous applications in targeted skin delivery for many active substances. Several studies have investigated their usage in the treatment of skin conditions such as eczema, psoriasis, bacterial infections, and skin cancer. Specifically, studies have shown an enhanced efficiency of the lipophilic calcipotriol and hydrophilic methotrexate for psoriasis treatment, while N-acetyl glucosamine incorporated in Precirol<sup>&#174;</sup>/Miglyol<sup>&#174;</sup> nanocarriers exhibited promising results in reducing the melanin distribution patterns caused by hyperpigmentation [<xref rid="B42-nanomaterials-15-01326" ref-type="bibr">42</xref>]. Acitretin incorporated in oleic acid and Precirol ATO 5 containing NLCs exhibited a significantly higher deposition of the active substance (<italic toggle="yes">p</italic> &lt; 0.05) in the skin versus the conventional gel, while clinical findings showed significantly improved results in the treatment of psoriasis [<xref rid="B43-nanomaterials-15-01326" ref-type="bibr">43</xref>]. Topical NLC preparations have also been formulated for the incorporation of non-steroidal anti-inflammatory (NSAIDs) and anti-arthritic drugs. Flurbiprofen-loaded NLCs using coconut oil, soya lecithin, and stearic acid showed increased penetration through the skin and better therapeutic performance up to 24 h [<xref rid="B44-nanomaterials-15-01326" ref-type="bibr">44</xref>]. Other examples of incorporated NSAIDs are ketoprofen, meloxicam, nimesulide, and diclofenac sodium, for which enhanced anti-inflammatory action was demonstrated, accompanied by good skin tolerance and reduced toxicity. Several corticosteroids have also been investigated as potential candidates for NLC loading. The percentage of the active substance absorbed beyond the stratum corneum as well as the amount retained in the skin were enhanced by 0.1% difluctolone valerate-loaded nanoparticles in comparison to the commercial Nerisone<sup>&#174;</sup> cream [<xref rid="B45-nanomaterials-15-01326" ref-type="bibr">45</xref>]. Fluocinolone NLCs have demonstrated improved drug solubility and enhanced deposition within the epidermis&#8212;the primary site of keratinocyte hyperproliferation. Selective targeting of the epidermis might also eliminate any adverse effects associated with systemic exposure [<xref rid="B65-nanomaterials-15-01326" ref-type="bibr">65</xref>]. Several dermal applications of antifungals such as luliconazole, quercetin, and fluconazole can be encountered. Luliconazole, although highly effective against Trichophyton species, exhibits limited skin penetration and retention. With the aim of surpassing this obstacle, Baghel et al. [<xref rid="B46-nanomaterials-15-01326" ref-type="bibr">46</xref>] examined the development of such nanocarrier systems. In the case of fluconazole-loaded NLCs, a significant reduction in fungal load was observed, as evidenced by the lowest colony-forming unit (cfu/mL) count in treated subjects [<xref rid="B42-nanomaterials-15-01326" ref-type="bibr">42</xref>]. Studies on systemic targeting for the treatment of Alzheimer&#8217;s disease were also found throughout the literature. Donepezil- and rivastigmine-loaded nanocarriers in transdermal drug delivery systems (TDDSs) have been developed, showing better therapeutic efficacy both in in vitro studies and animal tests, paving the way for alternative options in dementia management [<xref rid="B47-nanomaterials-15-01326" ref-type="bibr">47</xref>,<xref rid="B66-nanomaterials-15-01326" ref-type="bibr">66</xref>]</p><p>NLCs are also of great interest in the field of cosmetic industry due to their advantages of improved skin hydration, occlusion, biocompatibility, skin targeting, and molecule stabilization. Retinol has found a wide use in cosmeceutical applications as an active compound against wrinkle formation. However, its molecule is susceptible to oxidation and therefore is not easily stabilized. On this basis, retinol-loaded NLCs were formulated and found stable after storage for four weeks at temperatures of 25, 40, and 50 &#176;C. NLCs containing white willow bark extract, azelaic acid, and pathenol were also investigated in terms of enhancing skin hydration, with promising results [<xref rid="B42-nanomaterials-15-01326" ref-type="bibr">42</xref>].</p></sec><sec id="sec4dot4-nanomaterials-15-01326"><title>4.4. Ethosomes and Transfersomes</title><p>Ethosomes are structurally similar to liposomes but are distinguished by their high ethanol content, typically ranging from 20 to 50% [<xref rid="B20-nanomaterials-15-01326" ref-type="bibr">20</xref>] (<xref rid="nanomaterials-15-01326-f004" ref-type="fig">Figure 4</xref>).</p><p>This ethanol component imparts deformability to the vesicles, enhancing their ability to penetrate the skin. Ethanol is a well-established permeation enhancer and is believed to work synergistically with both the vesicular structure and the lipids within the skin. Specifically, ethosomes initially penetrate the skin by disrupting the highly organized layer of stratum corneum via their contained ethanol (&#8220;the ethanol effect&#8221;). The interaction of ethanol with the polar heads of the lipid bilayers increases their fluidity while decreasing their density, thereby resulting in nanocarriers with flexible features and the ability to penetrate into deeper tissues. Lastly, the fusion taking place between the phospholipids present in the SC and the ethosomal vesicle leads to enhanced drug delivery (&#8220;the ethosome effect&#8221;) [<xref rid="B48-nanomaterials-15-01326" ref-type="bibr">48</xref>,<xref rid="B67-nanomaterials-15-01326" ref-type="bibr">67</xref>] (<xref rid="nanomaterials-15-01326-f005" ref-type="fig">Figure 5</xref>).</p><p>A number of ethosome-based formulations can be applied for the treatment of skin pathologies such as psoriasis, dermatitis, acne vulgaris, and skin cancer or for the systemic treatment of inflammation, pulmonary diseases, bacterial, viral, or fungal infections, and many others. In more detail, psoralen, a photosensitive coumarin used for the treatment of the skin symptoms of psoriasis, was loaded in ethosomes to assess its efficacy. The study demonstrated a 6.56-fold increase in skin deposition of the active compound, along with enhanced permeation, compared to a conventional formulation [<xref rid="B48-nanomaterials-15-01326" ref-type="bibr">48</xref>]. Topical photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) is a treatment option to deal with the skin symptoms of psoriasis. The main mechanism of PDT is the modulation of cellular functions without causing cellular death. ALA specifically acts as a prodrug of the photosensitizer protoporphyrin IX (PpIX), formed after the in vivo application of ALA. Studies in murine models with hyperproliferative skin have shown that ALA-loaded nanocarriers improve ALA penetration and subsequently increase PpIX formation, while also reducing local TNF-&#945; levels when compared to a standard aqueous ALA solution [<xref rid="B68-nanomaterials-15-01326" ref-type="bibr">68</xref>]. Scientists have also incorporated methotrexate, an anti-psoriatic and anti-neoplastic agent, in ethosomes to assess if improved efficacy can be achieved. The results of the study revealed enhanced efficacy with lower toxicity accompanied by a better stability profile [<xref rid="B49-nanomaterials-15-01326" ref-type="bibr">49</xref>]. In terms of treating bacterial, viral, or fungal infections, active substances such as erythromycin [<xref rid="B50-nanomaterials-15-01326" ref-type="bibr">50</xref>], acyclovir [<xref rid="B51-nanomaterials-15-01326" ref-type="bibr">51</xref>], and fluconazole have been loaded in ethosome carriers and have been examined with regard to their penetration to the systemic circulation [<xref rid="B69-nanomaterials-15-01326" ref-type="bibr">69</xref>]. In all cases, enhanced skin penetration was detected when compared with conventional formulations. Pulmonary-targeted active substances have also been studied to be enclosed in ethosomes to enhance their systemic absorption from the skin. Specifically, ligustrazine-loaded ethosomes have shown promising results when administered through the transdermal route, with the ethosome patch group achieving a 2.09-fold increase in comparison to the oral route and a 2.12-fold increase in comparison to that of the conventional patches. The relative bioavailability was about 209.45%, while the oral one was only up to 98.63% [<xref rid="B52-nanomaterials-15-01326" ref-type="bibr">52</xref>].</p><p>Transfersomes, known for their high flexibility, are elastic vesicles composed of the standard bilayer and an edge activator (e.g., single-chain surfactant molecule), which is responsible for the weakening of the lipid bilayer and the increased deformability (<xref rid="nanomaterials-15-01326-f004" ref-type="fig">Figure 4</xref>). When applied on the surface of the skin, the transfersomes deform to pass through the keratinized layer to finally reach the deeper layers of the skin and the systemic circulation [<xref rid="B20-nanomaterials-15-01326" ref-type="bibr">20</xref>].</p><p>Transfersomes have been examined as vehicles for a variety of small molecules such as steroids, NSAIDs, and topical anesthetics, as well as peptides and proteins. Transfenac<sup>&#174;</sup>, a topical formulation containing diclofenac, has been shown to achieve therapeutically promising drug concentrations in target tissues. In preclinical studies, administration of a transfersome dose ranging from 0.25 to 2.00 mg/kg of rat body weight resulted in muscle tissue concentrations of 0.5 to 2.0 &#181;g/g. In contrast, a conventional hydrogel formulation yielded concentrations below 0.5 &#181;g/g [<xref rid="B70-nanomaterials-15-01326" ref-type="bibr">70</xref>]. Triamcinolone acetonide, a corticosteroid, was evaluated in terms of distribution and bioavailability in comparison to the commercially available lotion and cream products. The suppression of edema in mice was used as an indicator of the efficacy of the formulations. The results of the study indicated that the same biologic effect could be achieved with a 25-fold lower loaded dose of the active substance in the transfersomes. In this manner, a reduction in side effects is possible, without compromising the efficacy of the product [<xref rid="B53-nanomaterials-15-01326" ref-type="bibr">53</xref>]. Similar results were also recorded for dexamethasone-loaded transfersomes, where no lag time was detected after the application of the product, indicating the rapid release of the active substance to the site of action [<xref rid="B54-nanomaterials-15-01326" ref-type="bibr">54</xref>]. It is also reported that transfersomes can deliver similar amounts of insulin to the ones administered with subcutaneous injection. Insulin-loaded transfersomes composed of phosphatidylcholine were assessed after their applications in both mice and humans, and comparable levels to the ones of subcutaneous injections were measured, with only a difference in the lag time [<xref rid="B55-nanomaterials-15-01326" ref-type="bibr">55</xref>]. The potential of transfersomes for non-invasive vaccine delivery has also been investigated, with similar outcomes in the generation of antibodies in comparison to the standard used vaccines.</p><p>A summary of the advantages of each of the lipid-based drug delivery transdermal systems categories is illustrated in <xref rid="nanomaterials-15-01326-f006" ref-type="fig">Figure 6</xref>, while some of their main common advantages are enhanced penetration and bioavailability, a controlled release profile, and biocompatibility.</p></sec></sec><sec id="sec5-nanomaterials-15-01326"><title>5. Fast Clinical Translation of Lipid-Based Formulations for Transdermal Administration</title><p>Lipid-based formulations have already been marketed for the last thirty years as anticancer or antifungal medicines. The technology transfer from lab-scale to industrial batches, as well as the microfluidic-based techniques, is responsible for the fast clinical translation of liposomes and other lipid-based formulations. The preclinical models, i.e., human skin explants or reconstructed human epidermis, accelerate the evaluation of the prepared lipid-based formulations for transdermal administration [<xref rid="B6-nanomaterials-15-01326" ref-type="bibr">6</xref>].</p><p>Several preclinical studies have been conducted in the last decade for the enhanced transdermal delivery of diclofenac encapsulated in several lipid-based nanoformulations for the treatment of pain and inflammation [<xref rid="B71-nanomaterials-15-01326" ref-type="bibr">71</xref>,<xref rid="B72-nanomaterials-15-01326" ref-type="bibr">72</xref>].</p><p>A clinical study of 66 postmenopausal Brazilian women with climacteric symptoms of natural menopause who received progesterone and estradiol formulated in NLC in the forearm daily for 60 months to mimic the normal ovarian secretory pattern reveals the usage of the fast clinical translation of the aforementioned systems [<xref rid="B73-nanomaterials-15-01326" ref-type="bibr">73</xref>]. Lidocaine nanosystem behavior is also comparable to the marketed products for dermal delivery [<xref rid="B74-nanomaterials-15-01326" ref-type="bibr">74</xref>].</p><p>Last but not least, the combination of microneedles with liposomes has already been reported in the recent literature, where a glucose-responsive insulin delivery microneedle (MN) array patch is loaded with liposome nanoparticles containing glucose transporters bound with glucosamine-modified insulin. The results were very optimistic for the control of the levels of glucose and insulin in blood [<xref rid="B75-nanomaterials-15-01326" ref-type="bibr">75</xref>]. The clinical status of several lipid-based drug delivery systems for transdermal administration is presented in <xref rid="nanomaterials-15-01326-t002" ref-type="table">Table 2</xref>.</p></sec><sec id="sec6-nanomaterials-15-01326"><title>6. Quality by Design Approach for the Design and the Development of Lipid-Based Drug Delivery Systems</title><p>Researchers in academia, regulatory bodies, and pharmaceutical industries are working towards the quality assurance and the continuous improvement in the pharmaceutical products. Towards these efforts, evolving the Quality by Design (QbD) within the product development for the rational design of the formulation and manufacturing process embraces this scope. Based on the ICH Guidelines, i.e., Q8 for pharmaceutical development, Q9 for quality risk management, and Q10 for pharmaceutical quality systems, the QbD can define the Quality Target Product Profile (QTPP), the critical quality attributes (CQAs), the critical material attributes (CMAs), and the Critical Process Parameters (CPPs) of the product and further analyze the risk factors [<xref rid="B76-nanomaterials-15-01326" ref-type="bibr">76</xref>]. The QbD approach can be also applied towards the rational design and the development of lipid-based drug delivery systems, as it is presented in <xref rid="nanomaterials-15-01326-f007" ref-type="fig">Figure 7</xref>.</p><p>The critical quality attributes (CQAs) of the lipid-based nanoparticles that influence their performance during skin administration include particle size, particle size distribution, particle shape, and surface chemistry, taking also into account some critical material attributes (CMAs). The most critical aspect of a successful transdermal delivery of a lipid-based nanosystem is the effective skin permeation; thus, the choice and the optimization of the CQAs and CMAs during the formulation process should target this scope.</p><p>In terms of parameters such as size and size distribution, in general, nanoparticles larger than 600 nm in size are unable to penetrate to deeper skin layers, remaining only on or in the stratum corneum. Nanoparticles of size of 300 nm or less can penetrate and thus deliver more deeply, via the transfollicular route [<xref rid="B77-nanomaterials-15-01326" ref-type="bibr">77</xref>], in a size-dependent manner (the smaller the size, the higher the follicular transport, with more preferable embodiments at 10 to 210 nm sizes) [<xref rid="B78-nanomaterials-15-01326" ref-type="bibr">78</xref>]. Nanoparticles of 100 nm or less are suitable for deep skin penetration and allow the onset of action [<xref rid="B79-nanomaterials-15-01326" ref-type="bibr">79</xref>]. In particular, vesicles smaller than 70 nm can be found in both the viable epidermal and dermal layers via lipid transepidermal pathways, while those smaller than 36 nm can be absorbed via aqueous pores [<xref rid="B22-nanomaterials-15-01326" ref-type="bibr">22</xref>]. The combination of smaller sizes and higher vesicular elasticity has been proven to lead to a significant permeation enhancement effect. Two representative examples are the transferosomes (with a smaller vesicular size, typically &lt;300 nm, and higher elasticity, typically 5&#8211;8 times higher compared to conventional liposomes) and the ethosomes (with a smaller vesicular size, typically &lt;300 nm, and higher elasticity, typically 10&#8211;30 times higher compared to conventional liposomes), being ideal nanovesicles for skin permeation applications [<xref rid="B28-nanomaterials-15-01326" ref-type="bibr">28</xref>,<xref rid="B80-nanomaterials-15-01326" ref-type="bibr">80</xref>].</p><p>The mode of the interaction between the nanoparticles and the lipid bilayer is strictly influenced by the particle&#8217;s shape, volume, contact surface, local curvature at the point of contact, and initial orientation, therefore affecting the nanoparticle ability to permeate the lipid bilayer. For example, an ellipsoid particle is able to penetrate a lipid bilayer up to five times faster [<xref rid="B81-nanomaterials-15-01326" ref-type="bibr">81</xref>].</p><p>Surface charge is another key factor affecting the drug permeation and the in vivo behavior of nanoparticles after transdermal administration. Taking into account the physiology of the skin tissue, the normal skin has a net negative charge, in combination with the presence of sebum. Several recent studies suggest that lipid nanoparticles and sebum lipids should be attracted to each other to maximize drug penetration; therefore, positively charged nanoparticles are favored to exhibit better targeting [<xref rid="B82-nanomaterials-15-01326" ref-type="bibr">82</xref>]. Abdel-Mottaleb et al. [<xref rid="B78-nanomaterials-15-01326" ref-type="bibr">78</xref>] concluded that the presence of charge could enhance skin adhesion and the interaction of nanosystems, leading to a higher therapeutic effect on inflamed skin. In another studies, cationic nanoparticles are attracted by the negatively charged skin membrane [<xref rid="B83-nanomaterials-15-01326" ref-type="bibr">83</xref>], to transfer plasmid DNA to the skin [<xref rid="B84-nanomaterials-15-01326" ref-type="bibr">84</xref>], as well as cationic nanovaccines of transferosomes into microneedles escape endocytic compartments, allowing antigen processing via an MHC-I presentation pathway and increasing lymph node accumulation [<xref rid="B85-nanomaterials-15-01326" ref-type="bibr">85</xref>]. For the pH-responsive liposomes, the pH triggers several morphological changes, which lead to API release. The skin pH is acidic, around 5.5, while in deeper layers, the pH is higher. Taking into account these physiological conditions, the pH-responsive lipid-based nanoformulations are of particular interest for transdermal controlled drug release [<xref rid="B86-nanomaterials-15-01326" ref-type="bibr">86</xref>]. As mentioned above, the zeta potential is a crucial physicochemical parameter for the colloidal stability of lipid-based nanoformulations. The interaction with skin components and the penetration efficiency are also affected by the zeta potential. For instance, the positive charge of lipid-based nanoparticles improves the adhesion to the skin, the penetration, and the permeation because stronger electrostatic interactions are developed with the negatively charged components of the stratum corneum [<xref rid="B77-nanomaterials-15-01326" ref-type="bibr">77</xref>]. However, some negatively charged skin components have also been referred to. For example, compared with classic liposomes and ethanolic drug solutions, ethosomes are considered to increase the transdermal permeability of the encapsulated drug, due to their negative charge, in a higher ethanol concentration, leading to a continuous high transdermal flux [<xref rid="B87-nanomaterials-15-01326" ref-type="bibr">87</xref>].</p><p>Molecular dynamics simulations suggest that semi-hydrophilic particles can be adsorbed on the surface of the membrane bilayer, while hydrophobic nanoparticles penetrate the lipophilic core of cell membranes [<xref rid="B82-nanomaterials-15-01326" ref-type="bibr">82</xref>]. Yang et al. [<xref rid="B88-nanomaterials-15-01326" ref-type="bibr">88</xref>] developed a nanoemulsion for the delivery of retinyl that, due to its hydrophobic nature, exhibited highly enhanced results in the epidermis and dermis compared to conventional emulsions.</p><p>Moreover, the type of materials plays a key role in the later interaction of the nanoparticle with the skin. Starting from the typically used lipid, phosphatidylcholine, a well-established material of lipid nanocarriers, can act as a permeation enhancer for skin delivery of the drugs, being controlled by their phase transition temperature. In contrast, while the cholesterol increases membrane rigidity, it can downgrade the permeation through the skin [<xref rid="B89-nanomaterials-15-01326" ref-type="bibr">89</xref>]. Various fatty acids, being used in the formulation of SLNs and NLCs, can act as excellent skin penetration enhancers due to their ability to interact with stratum corneum lipids. Their penetration degree is controlled by their chemical structure, the length of the alkyl chain, and the degree of saturation [<xref rid="B82-nanomaterials-15-01326" ref-type="bibr">82</xref>]. The matrices of solid lipids are able to promote an extended and controlled drug release due to the limited drug diffusion from the matrix, being suitable for transdermal administration due to the small size and thus easier penetration. Apart from the lipids, the surfactants are considered to be permeation skin enhancers in a mode controlled by their hydrophilic&#8211;lipophilic balance (HLB), with the niosomes being representative examples. The HLB also affects the stability of the formulation and the complexation/encapsulation/incorporation of the API into the lipid-based nanocarrier [<xref rid="B30-nanomaterials-15-01326" ref-type="bibr">30</xref>].</p><p>Numerous other additional CQAs have been nominated for lipid-based nanosystems and are also applied in transdermal cases. Some of the typical CQAs are encapsulation efficiency, loading capacity, internal volume, phase transition temperature, morphology/lamellarity, etc. Lipids assays and degradation products of lipid component identification can affect particle size, polydispersity index, EE, loading capacity, and zeta potential, and hence may influence the therapeutic efficacy and the safety profile of the drug product [<xref rid="B90-nanomaterials-15-01326" ref-type="bibr">90</xref>].</p><p>Adhesion properties and elasticity are key parameters for skin permeation and therefore should be investigated during product and process development of transdermal products [<xref rid="B89-nanomaterials-15-01326" ref-type="bibr">89</xref>,<xref rid="B91-nanomaterials-15-01326" ref-type="bibr">91</xref>]. Elasticity allows the nanoparticle entrance via the small skin pores [<xref rid="B71-nanomaterials-15-01326" ref-type="bibr">71</xref>]. Spreadability is a quality attribute specific to topical formulations, such as ethosomes, depending on the viscosity of the formulation and has an impact on topical drug availability, and hence in the product efficacy. In transdermal delivery, viscosity may influence the drug diffusion rate at the microstructural level and, consequently, the delivered final dose and, therefore, the bioavailability [<xref rid="B92-nanomaterials-15-01326" ref-type="bibr">92</xref>].</p><p>Finally, in the case of nanoparticles, being enclosed into transdermal matrices, like reservoir-gradient, matrix diffusion-controlled or membrane-moderated systems, the CQAs of these matrices themselves should also be taken into account and typically include the following: peel adhesion, tack, release liner peel strength, shear strength, cold flow, residual solvents, residual monomers, microbial limits, the uniformity of dosage units, assay, permeation enhancer content, impurities and degradants, in vitro drug release profile, and (if present) preservative/antioxidant content [<xref rid="B93-nanomaterials-15-01326" ref-type="bibr">93</xref>]. In the Ishikawa diagram of <xref rid="nanomaterials-15-01326-f008" ref-type="fig">Figure 8</xref>, the main CQAs along with CMAs are presented.</p></sec><sec id="sec7-nanomaterials-15-01326"><title>7. Preparation and Characterization Methods of Lipid-Based Drug Delivery Systems</title><p>A precise definition of all the CPPs that are being evolved during the manufacturing process should take place during the development of the lipid-based drug delivery systems that would also help towards the selection of the most proper manufacturing method (<xref rid="nanomaterials-15-01326-f006" ref-type="fig">Figure 6</xref>). Moreover, the manufacturing environment is more challenging than that at smaller scales, as there is great difficulty in maintaining stable conditions of temperature, humidity, aseptic operation, etc., and achieving batch repeatability within the specifications.</p><p>Microfluidization techniques, the bubble method, the ether ejection method, and reverse phase evaporation are some of the main industrial techniques referred to as nanosystems intended for transdermal delivery [<xref rid="B94-nanomaterials-15-01326" ref-type="bibr">94</xref>]. Depending on the method, different CPPs can be identified and should be investigated during the process developments. Some of them are considered to be evaporation rate, flow rate, homogenization time/speed, humidity, number of cycles, phase addition order, pressure, stirring speed/time, temperature, etc. [<xref rid="B91-nanomaterials-15-01326" ref-type="bibr">91</xref>].</p><p>Apart from the advantages described in the previous paragraphs, the rational development of effective transdermal lipid-based products remains a challenge for the pharmaceutical industry. As it is analyzed above, the multifactorial formulation that should be taken into account in order to achieve effective skin permeation, along with the limitations of the already existing manufacturing methods, has restricted the market authorization of many products. Some of the manufacturing limitations include the limited scalability, the high batch-to-batch variance, and the increased stability requirements. The elevated development costs make it challenging to maintain high standards for quality, while it should be assured that appropriate environmental parameters (light, temperature, and humidity) are met during production, packaging, storage, and ultimate use [<xref rid="B95-nanomaterials-15-01326" ref-type="bibr">95</xref>].</p><p>The thorough characterization of lipid-based nanoformulations for transdermal administration is of paramount importance for their rational development as well. The interactions between lipid components and the API can be evaluated by thermal analysis techniques. Firstly, the physicochemical characteristics, i.e., size distribution, zeta potential, morphology, and shape, are crucial for uniformity and skin penetration ability, as well as stability. The drug loading, release, and stability studies are useful for the efficiency of API encapsulation and short- and long-term stability and storage conditions, respectively. The pH and the viscosity also reflect the formulation stability and applications in skin layers. After the detailed physicochemical characterization, the skin permeation and retention tests follow. For in vitro permeation tests, human or animal skin in Franz cells is widely used. Skin homogenization and API quantification for ex vivo skin retention are applied.</p></sec><sec id="sec8-nanomaterials-15-01326"><title>8. Regulatory Aspects of Lipid-Based Drug Delivery Systems</title><sec id="sec8dot1-nanomaterials-15-01326"><title>8.1. Characterization Requirements by Regulatory Framework</title><p>In the regulatory sense, some of the main requirements, among others, for the liposomal formulations, including the topically applied ones, are summarized below: chemical quality of lipids and other non-lipid components, lipid content, total drug substance content, encapsulated/free fractions of a drug substance, distribution of a drug substance within a liposome (e.g., surface, bilayer, interior), lipid-phase transition temperature, drug leakage from a carrier, degradation products of lipids and drug substances, stability of drugs, lipids, and other critical excipients in the finished product, particle size distribution and net charge (zeta potential), drug product viscosity, in vitro drug release, liposome integrity changes in response to environment or addition of other excipients, and stability of liposomal systems during storage and in-use conditions. As long as the manufacturing process is concerned, the identification of its key steps and its suitable controls are required, for example, monitoring the drug/lipidic moiety ratio at relevant manufacturing steps, description of the process, mechanism of liposomal drug loading, etc. [<xref rid="B96-nanomaterials-15-01326" ref-type="bibr">96</xref>].</p></sec><sec id="sec8dot2-nanomaterials-15-01326"><title>8.2. Challenges and Limitations of Regulatory Framework</title><p>Despite the plurality of the clinical trials registered in both the USA and the EU, few pharmaceutical products containing lipid vesicles (e.g., PevarylR Lipogel, MaxileneR cream, LipoxysanR, Supra-virR cream) have been market-authorized as topically applied pharmaceutical products [<xref rid="B96-nanomaterials-15-01326" ref-type="bibr">96</xref>]. Apart from the manufacturing aspects, the regulatory framework also creates challenges to their market authorization. For example, when major post-marketing variations are required, the complexity of a nanoparticulate formulation, even more via the skin route of administration, limits the ability of bioequivalence studies to assess the clinical equivalence of two products, requiring more expensive clinical trials [<xref rid="B96-nanomaterials-15-01326" ref-type="bibr">96</xref>]. Furthermore, the FDA requires an analytical study to be performed on the hair follicle penetration of topical nanoformulated products and on how the permeation mode is affected by the skin conditions (e.g., intact, damaged, diseased), while the EMA has suggested that permeation kinetics studies, like the in vitro permeation studies, for topical nanomedicine products be performed not only during the pharmaceutical development, but also as supportive studies for comparison reasons with the conventional products [<xref rid="B96-nanomaterials-15-01326" ref-type="bibr">96</xref>]. However, due to the variations in animal and human skin tissue, the current methods for bioequivalence access of transdermal delivery systems are not fully standardized, while the randomized controlled clinical trials are expensive and time-consuming and require a large number of participants that comply with ethical considerations [<xref rid="B95-nanomaterials-15-01326" ref-type="bibr">95</xref>]. A number of guidelines, guidance for industry, and reflection papers have been published by both the FDA and the EMA on the rational development of these products, covering issues on the presence of nanomaterial ingredients [<xref rid="B97-nanomaterials-15-01326" ref-type="bibr">97</xref>,<xref rid="B98-nanomaterials-15-01326" ref-type="bibr">98</xref>,<xref rid="B99-nanomaterials-15-01326" ref-type="bibr">99</xref>,<xref rid="B100-nanomaterials-15-01326" ref-type="bibr">100</xref>], as well as about product development and quality considerations of transdermal and topical delivery systems [<xref rid="B101-nanomaterials-15-01326" ref-type="bibr">101</xref>,<xref rid="B102-nanomaterials-15-01326" ref-type="bibr">102</xref>] that should be taken into account.</p></sec></sec><sec sec-type="conclusions" id="sec9-nanomaterials-15-01326"><title>9. Conclusions</title><p>The transdermal route could be a beneficial route of administration, especially due to its non-invasive character, although there are still obstacles impeding its usage. Lipid-based drug delivery systems could be promising candidates for pharmaceutical applications enabling efficient transcutaneous delivery due to their biocompatibility, versatility, and effective skin penetration. The most recent developments of lipid-based nanoparticles via the transdermal route of administration are presented. The physicochemical characteristics of all lipid-based nanoparticles are considered as CQAs and play a key role in their effectiveness. Studies regarding the added value and the applications of liposomes, ethosomes, solid lipid nanoparticles, transferosomes, and nanostructured lipid carriers showed how these systems enhance effectiveness and reduce adverse drug reactions. The thorough characterization of lipid-based nanoformulations for transdermal administration is of paramount importance for their rational development and fast clinical translation. Considering patients&#8217; unmet needs, the critical quality attributes, the existing challenges, and the regulatory framework are roadmaps for formulation scientists in order to design and develop transdermal lipid-based nanomedicines.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Writing&#8212;original draft preparation, L.A., E.T., and M.C.; writing&#8212;review and editing, N.P., P.P.D., and D.M.R.; supervision, N.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-nanomaterials-15-01326"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alkilani</surname><given-names>A.Z.</given-names></name><name name-style="western"><surname>Hamed</surname><given-names>R.</given-names></name><name name-style="western"><surname>Musleha</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sharaire</surname><given-names>Z.</given-names></name></person-group><article-title>Breaking Boundaries: The Advancements in Transdermal Delivery of Antibiotics</article-title><source>Drug Deliv.</source><year>2024</year><volume>31</volume><fpage>2304251</fpage><pub-id pub-id-type="doi">10.1080/10717544.2024.2304251</pub-id><pub-id pub-id-type="pmid">38241087</pub-id><pub-id pub-id-type="pmcid">PMC10802811</pub-id></element-citation></ref><ref id="B2-nanomaterials-15-01326"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sala</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diab</surname><given-names>R.</given-names></name><name name-style="western"><surname>Elaissari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fessi</surname><given-names>H.</given-names></name></person-group><article-title>Lipid Nanocarriers as Skin Drug Delivery Systems: Properties, Mechanisms of Skin Interactions and Medical Applications</article-title><source>Int. J. Pharm.</source><year>2018</year><volume>535</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.10.046</pub-id><pub-id pub-id-type="pmid">29111097</pub-id></element-citation></ref><ref id="B3-nanomaterials-15-01326"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akl</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Eldeen</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Kassem</surname><given-names>A.M.</given-names></name></person-group><article-title>Beyond Skin Deep: Phospholipid-Based Nanovesicles as Game-Changers in Transdermal Drug Delivery</article-title><source>AAPS PharmSciTech</source><year>2024</year><volume>25</volume><fpage>184</fpage><pub-id pub-id-type="doi">10.1208/s12249-024-02896-6</pub-id><pub-id pub-id-type="pmid">39138693</pub-id></element-citation></ref><ref id="B4-nanomaterials-15-01326"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pradhan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Saraf</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saraf</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.R.</given-names></name></person-group><article-title>Perspectives of Lipid-Based Drug Carrier Systems for Transdermal Delivery</article-title><source>Crit. Rev. Ther. Drug Carrier Syst.</source><year>2018</year><volume>35</volume><fpage>331</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1615/CritRevTherDrugCarrierSyst.2018020856</pub-id><pub-id pub-id-type="pmid">29972681</pub-id></element-citation></ref><ref id="B5-nanomaterials-15-01326"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name></person-group><article-title>Transdermal Drug Delivery</article-title><source>Nat. Biotechnol.</source><year>2008</year><volume>26</volume><fpage>1261</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1038/nbt.1504</pub-id><pub-id pub-id-type="pmid">18997767</pub-id><pub-id pub-id-type="pmcid">PMC2700785</pub-id></element-citation></ref><ref id="B6-nanomaterials-15-01326"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phatale</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vaiphei</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Jha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>D.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>A.</given-names></name></person-group><article-title>Overcoming Skin Barriers through Advanced Transdermal Drug Delivery Approaches</article-title><source>J. Control. Release</source><year>2022</year><volume>351</volume><fpage>361</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.09.025</pub-id><pub-id pub-id-type="pmid">36169040</pub-id></element-citation></ref><ref id="B7-nanomaterials-15-01326"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pielenhofer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sohl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Windbergs</surname><given-names>M.</given-names></name><name name-style="western"><surname>Langguth</surname><given-names>P.</given-names></name><name name-style="western"><surname>Radsak</surname><given-names>M.P.</given-names></name></person-group><article-title>Current Progress in Particle-Based Systems for Transdermal Vaccine Delivery</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>266</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.00266</pub-id><pub-id pub-id-type="pmid">32174915</pub-id><pub-id pub-id-type="pmcid">PMC7055421</pub-id></element-citation></ref><ref id="B8-nanomaterials-15-01326"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Jong</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Borm</surname><given-names>P.J.</given-names></name></person-group><article-title>Drug Delivery and Nanoparticles: Applications and Hazards</article-title><source>Int. J. Nanomed.</source><year>2008</year><volume>3</volume><fpage>133</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.2147/IJN.S596</pub-id><pub-id pub-id-type="pmcid">PMC2527668</pub-id><pub-id pub-id-type="pmid">18686775</pub-id></element-citation></ref><ref id="B9-nanomaterials-15-01326"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maiti</surname><given-names>P.</given-names></name></person-group><article-title>Targeted Therapy in Chronic Diseases Using Nanomaterial-Based Drug Delivery Vehicles</article-title><source>Signal Transduct. Target. Ther.</source><year>2019</year><volume>4</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1038/s41392-019-0068-3</pub-id><pub-id pub-id-type="pmid">31637012</pub-id><pub-id pub-id-type="pmcid">PMC6799838</pub-id></element-citation></ref><ref id="B10-nanomaterials-15-01326"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Smart Drug Delivery Systems for Precise Cancer Therapy</article-title><source>Acta Pharm. Sin. B</source><year>2022</year><volume>12</volume><fpage>4098</fpage><lpage>4121</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2022.08.013</pub-id><pub-id pub-id-type="pmid">36386470</pub-id><pub-id pub-id-type="pmcid">PMC9643298</pub-id></element-citation></ref><ref id="B11-nanomaterials-15-01326"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Billingsley</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Haley</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Wechsler</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Peppas</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name></person-group><article-title>Engineering Precision Nanoparticles for Drug Delivery</article-title><source>Nat. Rev. Drug Discov.</source><year>2021</year><volume>20</volume><fpage>101</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1038/s41573-020-0090-8</pub-id><pub-id pub-id-type="pmid">33277608</pub-id><pub-id pub-id-type="pmcid">PMC7717100</pub-id></element-citation></ref><ref id="B12-nanomaterials-15-01326"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Despotopoulou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lagopati</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pispas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gazouli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Demetzos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pippa</surname><given-names>N.</given-names></name></person-group><article-title>The Technology of Transdermal Delivery Nanosystems: From Design and Development to Preclinical Studies</article-title><source>Int. J. Pharm.</source><year>2022</year><volume>611</volume><fpage>121290</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.121290</pub-id><pub-id pub-id-type="pmid">34788674</pub-id></element-citation></ref><ref id="B13-nanomaterials-15-01326"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name></person-group><article-title>Gold Nanoparticles for Skin Drug Delivery</article-title><source>Int. J. Pharm.</source><year>2022</year><volume>625</volume><fpage>122122</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2022.122122</pub-id><pub-id pub-id-type="pmid">35987319</pub-id></element-citation></ref><ref id="B14-nanomaterials-15-01326"><label>14.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Benson</surname><given-names>H.A.E.</given-names></name></person-group><article-title>Skin Structure, Function, and Permeation</article-title><source>Topical and Transdermal Drug Delivery</source><person-group person-group-type="editor"><name name-style="western"><surname>Benson</surname><given-names>H.A.E.</given-names></name><name name-style="western"><surname>Watkinson</surname><given-names>A.C.</given-names></name></person-group><publisher-name>John Wiley &amp; Sons, Inc.</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2011</year><fpage>1</fpage><lpage>22</lpage></element-citation></ref><ref id="B15-nanomaterials-15-01326"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.F.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.B.</given-names></name></person-group><article-title>Enhancing Permeation of Drug Molecules Across the Skin via Delivery in Nanocarriers: Novel Strategies for Effective Transdermal Applications</article-title><source>Front. Bioeng. Biotechnol.</source><year>2021</year><volume>9</volume><elocation-id>646554</elocation-id><pub-id pub-id-type="doi">10.3389/fbioe.2021.646554</pub-id><pub-id pub-id-type="pmid">33855015</pub-id><pub-id pub-id-type="pmcid">PMC8039394</pub-id></element-citation></ref><ref id="B16-nanomaterials-15-01326"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawton</surname><given-names>S.</given-names></name></person-group><article-title>Skin 1: The Structure and Functions of the Skin</article-title><source>Nurs. Times</source><year>2019</year><volume>115</volume><fpage>30</fpage><lpage>33</lpage></element-citation></ref><ref id="B17-nanomaterials-15-01326"><label>17.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lane</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Watkinson</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Hadgraft</surname><given-names>J.</given-names></name></person-group><article-title>Passive Skin Permeation Enhancement</article-title><source>Topical and Transdermal Drug Delivery</source><person-group person-group-type="editor"><name name-style="western"><surname>Benson</surname><given-names>H.A.E.</given-names></name><name name-style="western"><surname>Watkinson</surname><given-names>A.C.</given-names></name></person-group><publisher-name>John Wiley &amp; Sons, Inc.</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2012</year><fpage>23</fpage><lpage>42</lpage></element-citation></ref><ref id="B18-nanomaterials-15-01326"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Mohapatra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Naseef</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Kurunian</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Alshadidi</surname><given-names>A.A.F.</given-names></name><name name-style="western"><surname>Alam</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Mirza</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Iqbal</surname><given-names>Z.</given-names></name></person-group><article-title>Potential of Lipid-Based Nanocarriers against Two Major Barriers to Drug Delivery&#8212;Skin and Blood&#8211;Brain Barrier</article-title><source>Membranes</source><year>2023</year><volume>13</volume><elocation-id>343</elocation-id><pub-id pub-id-type="doi">10.3390/membranes13030343</pub-id><pub-id pub-id-type="pmid">36984730</pub-id><pub-id pub-id-type="pmcid">PMC10058721</pub-id></element-citation></ref><ref id="B19-nanomaterials-15-01326"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalave</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>P.</given-names></name><name name-style="western"><surname>Misra</surname><given-names>A.</given-names></name></person-group><article-title>Transdermal Delivery of Macromolecules Using Nano Lipid Carriers</article-title><source>Curr. Pharm. Des.</source><year>2021</year><volume>27</volume><fpage>4330</fpage><lpage>4340</lpage><pub-id pub-id-type="doi">10.2174/1381612827666210820095330</pub-id><pub-id pub-id-type="pmid">34414868</pub-id></element-citation></ref><ref id="B20-nanomaterials-15-01326"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chacko</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Ghate</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Dsouza</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>S.A.</given-names></name></person-group><article-title>Lipid Vesicles: A Versatile Drug Delivery Platform for Dermal and Transdermal Applications</article-title><source>Colloids Surf. B Biointerfaces</source><year>2020</year><volume>195</volume><elocation-id>111262</elocation-id><pub-id pub-id-type="doi">10.1016/j.colsurfb.2020.111262</pub-id><pub-id pub-id-type="pmid">32736123</pub-id></element-citation></ref><ref id="B21-nanomaterials-15-01326"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dobreva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stefanov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andonova</surname><given-names>V.</given-names></name></person-group><article-title>Natural Lipids as Structural Components of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Topical Delivery</article-title><source>Curr. Pharm. Des.</source><year>2020</year><volume>26</volume><fpage>4524</fpage><lpage>4535</lpage><pub-id pub-id-type="doi">10.2174/1381612826666200514221649</pub-id><pub-id pub-id-type="pmid">32410552</pub-id></element-citation></ref><ref id="B22-nanomaterials-15-01326"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hua</surname><given-names>S.</given-names></name></person-group><article-title>Lipid-Based Nano-Delivery Systems for Skin Delivery of Drugs and Bioactives</article-title><source>Front. Pharmacol.</source><year>2015</year><volume>6</volume><elocation-id>219</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2015.00219</pub-id><pub-id pub-id-type="pmid">26483690</pub-id><pub-id pub-id-type="pmcid">PMC4588690</pub-id></element-citation></ref><ref id="B23-nanomaterials-15-01326"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name></person-group><article-title>Skin targeted lipid vesicles as novel nano carrier of ketoconazole: Characterization, in vitro and in vivo evaluation</article-title><source>J. Mater. Sci. Mater. Med.</source><year>2015</year><volume>26</volume><fpage>175</fpage><pub-id pub-id-type="doi">10.1007/s10856-015-5487-2</pub-id><pub-id pub-id-type="pmid">25825320</pub-id></element-citation></ref><ref id="B24-nanomaterials-15-01326"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gillet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Comp&#232;re</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lecomte</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hubert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ducat</surname><given-names>E.</given-names></name><name name-style="western"><surname>Evrard</surname><given-names>B.</given-names></name><name name-style="western"><surname>Piel</surname><given-names>G.</given-names></name></person-group><article-title>Skin penetration behaviour of liposomes as a function of their composition</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2011</year><volume>79</volume><fpage>43</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2011.01.011</pub-id><pub-id pub-id-type="pmid">21272638</pub-id></element-citation></ref><ref id="B25-nanomaterials-15-01326"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rangsimawong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Opanasopit</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rojanarata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ngawhirunpat</surname><given-names>T.</given-names></name></person-group><article-title>Terpene-Containing PEGylated Liposomes as Transdermal Carriers of a Hydrophilic Compound</article-title><source>Biol. Pharm. Bull.</source><year>2014</year><volume>37</volume><fpage>1936</fpage><lpage>1943</lpage><pub-id pub-id-type="doi">10.1248/bpb.b14-00535</pub-id><pub-id pub-id-type="pmid">25297807</pub-id></element-citation></ref><ref id="B26-nanomaterials-15-01326"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.A.</given-names></name></person-group><article-title>Ethosomes, binary ethosomes and transfersomes of terbinafine hydrochloride: A comparative study</article-title><source>Arch. Pharm. Res.</source><year>2012</year><volume>35</volume><fpage>109</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1007/s12272-012-0112-0</pub-id><pub-id pub-id-type="pmid">22297749</pub-id></element-citation></ref><ref id="B27-nanomaterials-15-01326"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pena-Rodr&#237;guez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Blanco-Fernandez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Campos</surname><given-names>F.</given-names></name></person-group><article-title>Epidermal Delivery of Retinyl Palmitate Loaded Transfersomes: Penetration and Biodistribution Studies</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>112</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12020112</pub-id><pub-id pub-id-type="pmid">32019144</pub-id><pub-id pub-id-type="pmcid">PMC7076369</pub-id></element-citation></ref><ref id="B28-nanomaterials-15-01326"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Touitou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dayan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bergelson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Godin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Eliaz</surname><given-names>M.</given-names></name></person-group><article-title>Ethosomes&#8212;Novel Vesicular Carriers for Enhanced Delivery: Characterization and Skin Penetration Properties</article-title><source>J. Control. Release</source><year>2000</year><volume>65</volume><fpage>403</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1016/S0168-3659(99)00222-9</pub-id><pub-id pub-id-type="pmid">10699298</pub-id></element-citation></ref><ref id="B29-nanomaterials-15-01326"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name></person-group><article-title>Mechanism investigation of ethosomes transdermal permeation</article-title><source>Int. J. Nanomed.</source><year>2017</year><volume>12</volume><fpage>3357</fpage><lpage>3364</lpage><pub-id pub-id-type="doi">10.2147/IJN.S134708</pub-id><pub-id pub-id-type="pmid">28490875</pub-id><pub-id pub-id-type="pmcid">PMC5413537</pub-id></element-citation></ref><ref id="B30-nanomaterials-15-01326"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardeike</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hommoss</surname><given-names>A.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>R.H.</given-names></name></person-group><article-title>Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products</article-title><source>Int. J. Pharm.</source><year>2009</year><volume>366</volume><fpage>170</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2008.10.003</pub-id><pub-id pub-id-type="pmid">18992314</pub-id></element-citation></ref><ref id="B31-nanomaterials-15-01326"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Radtke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wissing</surname><given-names>S.A.</given-names></name></person-group><article-title>Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations</article-title><source>Adv. Drug Deliv. Rev.</source><year>2002</year><volume>54</volume><issue>(Suppl. S1)</issue><fpage>S131</fpage><lpage>S155</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(02)00118-7</pub-id><pub-id pub-id-type="pmid">12460720</pub-id></element-citation></ref><ref id="B32-nanomaterials-15-01326"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moghddam</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Ahad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aqil</surname><given-names>M.</given-names></name><name name-style="western"><surname>Imam</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Sultana</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.</given-names></name></person-group><article-title>Optimization of nanostructured lipid carriers for topical delivery of nimesulide using Box&#8211;Behnken design approach</article-title><source>Artif. Cells Nanomed. Biotechnol.</source><year>2017</year><volume>45</volume><fpage>617</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.3109/21691401.2016.1167699</pub-id><pub-id pub-id-type="pmid">27050533</pub-id></element-citation></ref><ref id="B33-nanomaterials-15-01326"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosny</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Aldawsari</surname><given-names>H.M.</given-names></name></person-group><article-title>Avanafil Liposomes as Transdermal Drug Delivery for Erectile Dysfunction Treatment: Preparation, Characterization, and In Vitro, Ex Vivo and In Vivo Studies</article-title><source>Trop. J. Pharm. Res.</source><year>2015</year><volume>14</volume><fpage>559</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.4314/tjpr.v14i4.1</pub-id></element-citation></ref><ref id="B34-nanomaterials-15-01326"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bi</surname><given-names>Y.</given-names></name></person-group><article-title>Liposomal Vitamin D3 as an Anti-Aging Agent for the Skin</article-title><source>Pharmaceutics</source><year>2019</year><volume>11</volume><elocation-id>311</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics11070311</pub-id><pub-id pub-id-type="pmid">31277236</pub-id><pub-id pub-id-type="pmcid">PMC6680917</pub-id></element-citation></ref><ref id="B35-nanomaterials-15-01326"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapoor</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>D&#8217;Souza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aibani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Sandbhor</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kumari</surname><given-names>D.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>R.</given-names></name></person-group><article-title>Stable Liposome in Cosmetic Platforms for Transdermal Folic Acid Delivery for Fortification and Treatment of Micronutrient Deficiencies</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><elocation-id>16122</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-34205-0</pub-id><pub-id pub-id-type="pmid">30382116</pub-id><pub-id pub-id-type="pmcid">PMC6208427</pub-id></element-citation></ref><ref id="B36-nanomaterials-15-01326"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franz&#232;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Angelo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Casiraghi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Minghetti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cilurzo</surname><given-names>F.</given-names></name></person-group><article-title>Design of Liposomal Lidocaine/Cannabidiol Fixed Combinations for Local Neuropathic Pain Treatment</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>1915</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14091915</pub-id><pub-id pub-id-type="pmid">36145663</pub-id><pub-id pub-id-type="pmcid">PMC9504077</pub-id></element-citation></ref><ref id="B37-nanomaterials-15-01326"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rostamkalaei</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Akbari</surname><given-names>J.</given-names></name><name name-style="western"><surname>Saeedi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morteza-Semnani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nokhodchi</surname><given-names>A.</given-names></name></person-group><article-title>Topical Gel of Metformin Solid Lipid Nanoparticles: A Hopeful Promise as a Dermal Delivery System</article-title><source>Colloids Surf. B Biointerfaces</source><year>2019</year><volume>175</volume><fpage>150</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2018.11.072</pub-id><pub-id pub-id-type="pmid">30530000</pub-id></element-citation></ref><ref id="B38-nanomaterials-15-01326"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butani</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yewale</surname><given-names>C.</given-names></name><name name-style="western"><surname>Misra</surname><given-names>A.</given-names></name></person-group><article-title>Topical Amphotericin B Solid Lipid Nanoparticles: Design and Development</article-title><source>Colloids Surf. B Biointerfaces</source><year>2016</year><volume>139</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2015.07.032</pub-id><pub-id pub-id-type="pmid">26700229</pub-id></element-citation></ref><ref id="B39-nanomaterials-15-01326"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name></person-group><article-title>Targeting of Eugenol-Loaded Solid Lipid Nanoparticles to the Epidermal Layer of Human Skin</article-title><source>Nanomedicine</source><year>2014</year><volume>9</volume><fpage>1223</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.2217/nnm.13.33</pub-id><pub-id pub-id-type="pmid">23987096</pub-id></element-citation></ref><ref id="B40-nanomaterials-15-01326"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geetha</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kapila</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prakash</surname><given-names>O.</given-names></name><name name-style="western"><surname>Deol</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Kakkar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>I.P.</given-names></name></person-group><article-title>Sesamol-Loaded Solid Lipid Nanoparticles for Treatment of Skin Cancer</article-title><source>J. Drug Target.</source><year>2015</year><volume>23</volume><fpage>159</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.3109/1061186X.2014.965717</pub-id><pub-id pub-id-type="pmid">25268273</pub-id></element-citation></ref><ref id="B41-nanomaterials-15-01326"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shrotriya</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Vidhate</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>M.S.</given-names></name></person-group><article-title>Formulation and Development of Silybin-Loaded Solid Lipid Nanoparticle Enriched Gel for Irritant Contact Dermatitis</article-title><source>Drug Deliv. Transl. Res.</source><year>2017</year><volume>41</volume><fpage>164</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.jddst.2017.07.006</pub-id><pub-id pub-id-type="pmid">27981502</pub-id></element-citation></ref><ref id="B42-nanomaterials-15-01326"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fitriani</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Avanti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rosana</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Surini</surname><given-names>S.</given-names></name></person-group><article-title>Nanostructured Lipid Carriers: A Prospective Dermal Drug Delivery System for Natural Active Ingredients</article-title><source>Pharmacia</source><year>2024</year><volume>71</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.3897/pharmacia.71.e115849</pub-id></element-citation></ref><ref id="B43-nanomaterials-15-01326"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Petkar</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Sawant</surname><given-names>K.K.</given-names></name></person-group><article-title>Development, Evaluation and Clinical Studies of Acitretin Loaded Nanostructured Lipid Carriers for Topical Treatment of Psoriasis</article-title><source>Int. J. Pharm.</source><year>2010</year><volume>401</volume><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2010.09.007</pub-id><pub-id pub-id-type="pmid">20858539</pub-id></element-citation></ref><ref id="B44-nanomaterials-15-01326"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawadkar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kishore</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>M.K.</given-names></name></person-group><article-title>Formulation, Characterization and In Vitro-In Vivo Evaluation of Flurbiprofen-Loaded Nanostructured Lipid Carriers for Transdermal Delivery</article-title><source>Drug Dev. Ind. Pharm.</source><year>2013</year><volume>39</volume><fpage>569</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.3109/03639045.2012.686509</pub-id><pub-id pub-id-type="pmid">22639934</pub-id></element-citation></ref><ref id="B45-nanomaterials-15-01326"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdel-Salam</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Mahmoud</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Ammar</surname><given-names>H.O.</given-names></name><name name-style="western"><surname>Elkheshen</surname><given-names>S.A.</given-names></name></person-group><article-title>Nanostructured Lipid Carriers as Semisolid Topical Delivery Formulations for Diflucortolone Valerate</article-title><source>J. Liposome Res.</source><year>2017</year><volume>27</volume><fpage>41</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.3109/08982104.2016.1149866</pub-id><pub-id pub-id-type="pmid">26956098</pub-id></element-citation></ref><ref id="B46-nanomaterials-15-01326"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baghel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Pirani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sravani</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Bhemisetty</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ananthamurthy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Aranjani</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>S.A.</given-names></name></person-group><article-title>Luliconazole-Loaded Nanostructured Lipid Carriers for Topical Treatment of Superficial Tinea Infections</article-title><source>Dermatol. Ther.</source><year>2020</year><volume>33</volume><fpage>e13959</fpage><pub-id pub-id-type="doi">10.1111/dth.13959</pub-id><pub-id pub-id-type="pmid">32618400</pub-id></element-citation></ref><ref id="B47-nanomaterials-15-01326"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendes</surname><given-names>I.T.</given-names></name><name name-style="western"><surname>Ruela</surname><given-names>A.L.M.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Freitas</surname><given-names>J.T.J.</given-names></name><name name-style="western"><surname>Bonfilio</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>G.R.</given-names></name></person-group><article-title>Development and Characterization of Nanostructured Lipid Carrier-Based Gels for the Transdermal Delivery of Donepezil</article-title><source>Colloids Surf. B Biointerfaces</source><year>2019</year><volume>177</volume><fpage>274</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2019.02.007</pub-id><pub-id pub-id-type="pmid">30763792</pub-id></element-citation></ref><ref id="B48-nanomaterials-15-01326"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paiva-Santos</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Guerra</surname><given-names>C.</given-names></name><name name-style="western"><surname>Peixoto</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pereira-Silva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zeinali</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mascarenhas-Melo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Veiga</surname><given-names>F.</given-names></name></person-group><article-title>Ethosomes as Nanocarriers for the Development of Skin Delivery Formulations</article-title><source>Pharm. Res.</source><year>2021</year><volume>38</volume><fpage>947</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1007/s11095-021-03053-5</pub-id><pub-id pub-id-type="pmid">34036520</pub-id></element-citation></ref><ref id="B49-nanomaterials-15-01326"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubey</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nahar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saraf</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>N.K.</given-names></name></person-group><article-title>Dermal and Transdermal Delivery of an Anti-Psoriatic Agent via Ethanolic Liposomes</article-title><source>J. Control. Release</source><year>2007</year><volume>123</volume><fpage>148</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2007.08.005</pub-id><pub-id pub-id-type="pmid">17884226</pub-id></element-citation></ref><ref id="B50-nanomaterials-15-01326"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Godin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Touitou</surname><given-names>E.</given-names></name></person-group><article-title>Erythromycin Ethosomal Systems: Physicochemical Characterization and Enhanced Antibacterial Activity</article-title><source>Curr. Drug Deliv.</source><year>2005</year><volume>2</volume><fpage>269</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.2174/1567201054367931</pub-id><pub-id pub-id-type="pmid">16305429</pub-id></element-citation></ref><ref id="B51-nanomaterials-15-01326"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.A.</given-names></name></person-group><article-title>Synergistic Penetration of Ethosomes and Lipophilic Prodrug on the Transdermal Delivery of Acyclovir</article-title><source>Arch. Pharm. Res.</source><year>2010</year><volume>33</volume><fpage>567</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1007/s12272-010-0411-2</pub-id><pub-id pub-id-type="pmid">20422366</pub-id></element-citation></ref><ref id="B52-nanomaterials-15-01326"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name></person-group><article-title>Preparation of a Ligustrazine Ethosome Patch and Its Evaluation In Vitro and In Vivo</article-title><source>Int. J. Nanomed.</source><year>2011</year><volume>6</volume><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.2147/IJN.S16044</pub-id><pub-id pub-id-type="pmid">21499422</pub-id><pub-id pub-id-type="pmcid">PMC3075898</pub-id></element-citation></ref><ref id="B53-nanomaterials-15-01326"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cevc</surname><given-names>G.</given-names></name><name name-style="western"><surname>Blume</surname><given-names>G.</given-names></name></person-group><article-title>Biological Activity and Characteristics of Triamcinolone Acetonide Formulated with the Self-Regulating Drug Carriers, Transfersomes</article-title><source>Biochim. Biophys. Acta Biomembr.</source><year>2003</year><volume>1614</volume><fpage>156</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/S0005-2736(03)00172-X</pub-id><pub-id pub-id-type="pmid">12896808</pub-id></element-citation></ref><ref id="B54-nanomaterials-15-01326"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>P.</given-names></name><name name-style="western"><surname>Umamaheshwari</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>N.K.</given-names></name></person-group><article-title>Transfersomes--a novel vesicular carrier for enhanced transdermal delivery: Development, characterization, and performance evaluation</article-title><source>Drug Dev. Ind. Pharm.</source><year>2003</year><volume>29</volume><fpage>1013</fpage><lpage>1026</lpage><pub-id pub-id-type="doi">10.1081/DDC-120025458</pub-id><pub-id pub-id-type="pmid">14606665</pub-id></element-citation></ref><ref id="B55-nanomaterials-15-01326"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cevc</surname><given-names>G.</given-names></name></person-group><article-title>Transdermal Drug Delivery of Insulin with Ultradeformable Carriers</article-title><source>Clin. Pharmacokinet.</source><year>2003</year><volume>42</volume><fpage>461</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.2165/00003088-200342050-00004</pub-id><pub-id pub-id-type="pmid">12739984</pub-id></element-citation></ref><ref id="B56-nanomaterials-15-01326"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pierre</surname><given-names>M.B.R.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>I.M.</given-names></name></person-group><article-title>Liposomal Systems as Drug Delivery Vehicles for Dermal and Transdermal Applications</article-title><source>Arch. Dermatol. Res.</source><year>2011</year><volume>303</volume><fpage>607</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1007/s00403-011-1166-4</pub-id><pub-id pub-id-type="pmid">21805180</pub-id></element-citation></ref><ref id="B57-nanomaterials-15-01326"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yarosh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>J.</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hawk</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rafal</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>P.</given-names></name></person-group><article-title>Effect of Topically Applied T4 Endonuclease V in Liposomes on Skin Cancer in Xeroderma Pigmentosum: A Randomised Study</article-title><source>Lancet</source><year>2001</year><volume>357</volume><fpage>926</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)04214-8</pub-id><pub-id pub-id-type="pmid">11289350</pub-id></element-citation></ref><ref id="B58-nanomaterials-15-01326"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yarosh</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Potten</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>P.</given-names></name></person-group><article-title>Photoprotection by Topical DNA Repair Enzymes: Molecular Correlates of Clinical Studies</article-title><source>Photochem. Photobiol.</source><year>1999</year><volume>69</volume><fpage>136</fpage><lpage>140</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1562/0031-8655(1999)069&amp;#x0003c;0136:PBTDRE&amp;#x0003e;2.3.CO;2</pub-id><pub-id pub-id-type="pmid">10048308</pub-id></element-citation></ref><ref id="B59-nanomaterials-15-01326"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montoto</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Muraca</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>M.E.</given-names></name></person-group><article-title>Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects</article-title><source>Front. Mol. Biosci.</source><year>2020</year><volume>7</volume><elocation-id>587997</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2020.587997</pub-id><pub-id pub-id-type="pmid">33195435</pub-id><pub-id pub-id-type="pmcid">PMC7662460</pub-id></element-citation></ref><ref id="B60-nanomaterials-15-01326"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jyothi</surname><given-names>V.G.S.S.</given-names></name><name name-style="western"><surname>Ghouse</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Khatri</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Nanduri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Madan</surname><given-names>J.</given-names></name></person-group><article-title>Lipid Nanoparticles in Topical Dermal Drug Delivery: Does Chemistry of Lipid Persuade Skin Penetration?</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2022</year><volume>69</volume><fpage>103176</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2022.103176</pub-id></element-citation></ref><ref id="B61-nanomaterials-15-01326"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aggarwal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Goindi</surname><given-names>S.</given-names></name></person-group><article-title>Preparation and In Vivo Evaluation of Solid Lipid Nanoparticles of Griseofulvin for Dermal Use</article-title><source>J. Biomed. Nanotechnol.</source><year>2013</year><volume>9</volume><fpage>564</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1166/jbn.2013.1569</pub-id><pub-id pub-id-type="pmid">23621015</pub-id></element-citation></ref><ref id="B62-nanomaterials-15-01326"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khare</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gulbake</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S.K.</given-names></name></person-group><article-title>Design and development of solid lipid nanoparticles for topical delivery of an anti-fungal agent</article-title><source>Drug Deliv.</source><year>2010</year><volume>17</volume><fpage>443</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.3109/10717544.2010.483252</pub-id><pub-id pub-id-type="pmid">20486871</pub-id></element-citation></ref><ref id="B63-nanomaterials-15-01326"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montenegro</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sinico</surname><given-names>C.</given-names></name><name name-style="western"><surname>Castangia</surname><given-names>I.</given-names></name><name name-style="western"><surname>Carbone</surname><given-names>C.</given-names></name><name name-style="western"><surname>Puglisi</surname><given-names>G.</given-names></name></person-group><article-title>Idebenone-Loaded Solid Lipid Nanoparticles for Drug Delivery to the Skin: In Vitro Evaluation</article-title><source>Int. J. Pharm.</source><year>2012</year><volume>434</volume><fpage>169</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2012.05.046</pub-id><pub-id pub-id-type="pmid">22659127</pub-id></element-citation></ref><ref id="B64-nanomaterials-15-01326"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeon</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name></person-group><article-title>A Retinyl Palmitate-Loaded Solid Lipid Nanoparticle System: Effect of Surface Modification with Dicetyl Phosphate on Skin Permeation In Vitro and Antiwrinkle Effect In Vivo</article-title><source>Int. J. Pharm.</source><year>2013</year><volume>452</volume><fpage>311</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2013.05.023</pub-id><pub-id pub-id-type="pmid">23702002</pub-id></element-citation></ref><ref id="B65-nanomaterials-15-01326"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pradhan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Murthy</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.R.</given-names></name></person-group><article-title>Design, Characterization and Skin Permeating Potential of Fluocinolone Acetonide Loaded Nanostructured Lipid Carriers for Topical Treatment of Psoriasis</article-title><source>Steroids</source><year>2015</year><volume>101</volume><fpage>56</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.steroids.2015.05.012</pub-id><pub-id pub-id-type="pmid">26049018</pub-id></element-citation></ref><ref id="B66-nanomaterials-15-01326"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chauhan</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P.K.</given-names></name></person-group><article-title>Optimization and Characterization of Rivastigmine Nanolipid Carrier Loaded Transdermal Patches for the Treatment of Dementia</article-title><source>Chem. Phys. Lipids</source><year>2019</year><volume>224</volume><fpage>104794</fpage><pub-id pub-id-type="doi">10.1016/j.chemphyslip.2019.104794</pub-id><pub-id pub-id-type="pmid">31361985</pub-id></element-citation></ref><ref id="B67-nanomaterials-15-01326"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y.</given-names></name></person-group><article-title>Ethosomes: A Promising Drug Delivery Platform for Transdermal Application</article-title><source>Chemistry</source><year>2024</year><volume>6</volume><fpage>993</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.3390/chemistry6050058</pub-id></element-citation></ref><ref id="B68-nanomaterials-15-01326"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>Y.H.</given-names></name></person-group><article-title>Topical Delivery of 5-Aminolevulinic Acid-Encapsulated Ethosomes in a Hyperproliferative Skin Animal Model Using the CLSM Technique to Evaluate the Penetration Behavior</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2009</year><volume>73</volume><fpage>391</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2009.07.011</pub-id><pub-id pub-id-type="pmid">19660544</pub-id></element-citation></ref><ref id="B69-nanomaterials-15-01326"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhalaria</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Naik</surname><given-names>S.</given-names></name><name name-style="western"><surname>Misra</surname><given-names>A.N.</given-names></name></person-group><article-title>Ethosomes: A Novel System for Antifungal Drugs in the Treatment of Topical Fungal Disease</article-title><source>Indian J. Exp. Biol.</source><year>2009</year><volume>47</volume><fpage>368</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">19579803</pub-id></element-citation></ref><ref id="B70-nanomaterials-15-01326"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cevc</surname><given-names>G.</given-names></name><name name-style="western"><surname>Blume</surname><given-names>G.</given-names></name></person-group><article-title>New, Highly Efficient Formulation of Diclofenac for the Topical, Transdermal Administration in Ultradeformable Drug Carriers, Transfersomes</article-title><source>Biochim. Biophys. Acta Biomembr.</source><year>2001</year><volume>1514</volume><fpage>191</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/S0005-2736(01)00369-8</pub-id><pub-id pub-id-type="pmid">11557020</pub-id></element-citation></ref><ref id="B71-nanomaterials-15-01326"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghanbarzadeh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Arami</surname><given-names>S.</given-names></name></person-group><article-title>Enhanced Transdermal Delivery of Diclofenac Sodium via Conventional Liposomes, Ethosomes, and Transfersomes</article-title><source>BioMed Res. Int.</source><year>2013</year><volume>2013</volume><elocation-id>616810</elocation-id><pub-id pub-id-type="doi">10.1155/2013/616810</pub-id><pub-id pub-id-type="pmid">23936825</pub-id><pub-id pub-id-type="pmcid">PMC3725948</pub-id></element-citation></ref><ref id="B72-nanomaterials-15-01326"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Goyal</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thakur</surname><given-names>K.</given-names></name><name name-style="western"><surname>Raza</surname><given-names>K.</given-names></name><name name-style="western"><surname>Katare</surname><given-names>O.P.</given-names></name></person-group><article-title>Novel Elastic Membrane Vesicles (EMVs) and Ethosomes-Mediated Effective Topical Delivery of Aceclofenac: A New Therapeutic Approach for Pain and Inflammation</article-title><source>Drug Deliv.</source><year>2016</year><volume>23</volume><fpage>3135</fpage><lpage>3145</lpage><pub-id pub-id-type="doi">10.3109/10717544.2016.1155244</pub-id><pub-id pub-id-type="pmid">26960815</pub-id></element-citation></ref><ref id="B73-nanomaterials-15-01326"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Botelho</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Queiroz</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Barros</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guerreiro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fechine</surname><given-names>P.</given-names></name><name name-style="western"><surname>Umbelino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lyra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Borges</surname><given-names>B.</given-names></name><name name-style="western"><surname>Freitas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Queiroz</surname><given-names>D.C.</given-names></name><etal/></person-group><article-title>Nanostructured Transdermal Hormone Replacement Therapy for Relieving Menopausal Symptoms: A Confocal Raman Spectroscopy Study</article-title><source>Clinics</source><year>2014</year><volume>69</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.6061/clinics/2014(02)01</pub-id><pub-id pub-id-type="pmid">24519196</pub-id><pub-id pub-id-type="pmcid">PMC3912337</pub-id></element-citation></ref><ref id="B74-nanomaterials-15-01326"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pathak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nagarsenker</surname><given-names>M.</given-names></name></person-group><article-title>Formulation and Evaluation of Lidocaine Lipid Nanosystems for Dermal Delivery</article-title><source>AAPS PharmSciTech</source><year>2009</year><volume>10</volume><fpage>985</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1208/s12249-009-9287-1</pub-id><pub-id pub-id-type="pmid">19641997</pub-id><pub-id pub-id-type="pmcid">PMC2802165</pub-id></element-citation></ref><ref id="B75-nanomaterials-15-01326"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>X.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Microneedle Patches Loaded with Nanovesicles for Glucose Transporter-Mediated Insulin Delivery</article-title><source>ACS Nano</source><year>2022</year><volume>16</volume><fpage>18223</fpage><lpage>18231</lpage><pub-id pub-id-type="doi">10.1021/acsnano.2c05687</pub-id><pub-id pub-id-type="pmid">36322923</pub-id><pub-id pub-id-type="pmcid">PMC10738036</pub-id></element-citation></ref><ref id="B76-nanomaterials-15-01326"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Naquvi</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Haider</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.A.</given-names></name></person-group><article-title>Quality by Design&#8212;Newer Technique for Pharmaceutical Product Development</article-title><source>Intell. Pharm.</source><year>2024</year><volume>2</volume><fpage>122</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.ipha.2023.10.004</pub-id></element-citation></ref><ref id="B77-nanomaterials-15-01326"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Blume</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fahr</surname><given-names>A.</given-names></name></person-group><article-title>Particle Size of Liposomes Influences Dermal Delivery of Substances into Skin</article-title><source>Int. J. Pharm.</source><year>2003</year><volume>258</volume><fpage>141</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/S0378-5173(03)00183-2</pub-id><pub-id pub-id-type="pmid">12753761</pub-id></element-citation></ref><ref id="B78-nanomaterials-15-01326"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdel-Mottaleb</surname><given-names>M.M.A.</given-names></name><name name-style="western"><surname>Mortada</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>El-Shamy</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Awad</surname><given-names>G.A.</given-names></name></person-group><article-title>Physically Cross-Linked Polyvinyl Alcohol for the Topical Delivery of Fluconazole</article-title><source>Drug Dev. Ind. Pharm.</source><year>2009</year><volume>35</volume><fpage>311</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1080/03639040802325893</pub-id><pub-id pub-id-type="pmid">18798033</pub-id></element-citation></ref><ref id="B79-nanomaterials-15-01326"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adib</surname><given-names>Z.M.</given-names></name><name name-style="western"><surname>Ghanbarzadeh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kouhsoltani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yari Khosroshahi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hamishehkar</surname><given-names>H.</given-names></name></person-group><article-title>The Effect of Particle Size on the Deposition of Solid Lipid Nanoparticles in Different Skin Layers: A Histological Study</article-title><source>Adv. Pharm. Bull.</source><year>2016</year><volume>6</volume><fpage>31</fpage><pub-id pub-id-type="doi">10.15171/apb.2016.06</pub-id><pub-id pub-id-type="pmid">27123415</pub-id><pub-id pub-id-type="pmcid">PMC4845546</pub-id></element-citation></ref><ref id="B80-nanomaterials-15-01326"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Balakrishnan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shim</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.D.</given-names></name></person-group><article-title>A Novel Vesicular Carrier, Transethosome, for Enhanced Skin Delivery of Voriconazole: Characterization and In Vitro/In Vivo Evaluation</article-title><source>Colloids Surf. B Biointerfaces</source><year>2012</year><volume>92</volume><fpage>299</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2011.12.004</pub-id><pub-id pub-id-type="pmid">22205066</pub-id></element-citation></ref><ref id="B81-nanomaterials-15-01326"><label>81.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Gomathi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rajeshwari</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kanchana</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sudha</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Parthasarathy</surname><given-names>K.</given-names></name></person-group><article-title>Impact of Nanoparticle Shape, Size, and Properties of the Sustainable Nanocomposites</article-title><source>Sustainable Polymer Composites and Nanocomposites</source><person-group person-group-type="editor"><name name-style="western"><surname>Inamuddin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mavinkere Rangappa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Asiri</surname><given-names>A.M.</given-names></name></person-group><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2019</year><fpage>313</fpage><lpage>336</lpage></element-citation></ref><ref id="B82-nanomaterials-15-01326"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akombaetwa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ilangala</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Thom</surname><given-names>L.</given-names></name><name name-style="western"><surname>Memvanga</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Witika</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Buya</surname><given-names>A.B.</given-names></name></person-group><article-title>Current Advances in Lipid Nanosystems Intended for Topical and Transdermal Drug Delivery Applications</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>656</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15020656</pub-id><pub-id pub-id-type="pmid">36839978</pub-id><pub-id pub-id-type="pmcid">PMC9967415</pub-id></element-citation></ref><ref id="B83-nanomaterials-15-01326"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Su</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Preparation and Evaluation of Lidocaine Hydrochloride-Loaded TAT-Conjugated Polymeric Liposomes for Transdermal Delivery</article-title><source>Int. J. Pharm.</source><year>2013</year><volume>441</volume><fpage>748</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2012.10.019</pub-id><pub-id pub-id-type="pmid">23089577</pub-id></element-citation></ref><ref id="B84-nanomaterials-15-01326"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.K.</given-names></name></person-group><article-title>Charge-Mediated Topical Delivery of Plasmid DNA with Cationic Lipid Nanoparticles to the Skin</article-title><source>Colloids Surf. B Biointerfaces</source><year>2014</year><volume>116</volume><fpage>582</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2014.01.053</pub-id><pub-id pub-id-type="pmid">24631964</pub-id></element-citation></ref><ref id="B85-nanomaterials-15-01326"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>M.</given-names></name></person-group><article-title>A Surface Charge Dependent Enhanced Th1 Antigen-Specific Immune Response in Lymph Nodes by Transfersome-Based Nanovaccine-Loaded Dissolving Microneedle-Assisted Transdermal Immunization</article-title><source>J. Mater. Chem. B</source><year>2019</year><volume>7</volume><fpage>4854</fpage><lpage>4866</lpage><pub-id pub-id-type="doi">10.1039/C9TB00448C</pub-id><pub-id pub-id-type="pmid">31389952</pub-id></element-citation></ref><ref id="B86-nanomaterials-15-01326"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Song</surname><given-names>S.</given-names></name></person-group><article-title>pH-Sensitive Imidazole-Modified Liposomes for Enhanced Transdermal Delivery</article-title><source>Pharmaceuticals</source><year>2022</year><volume>15</volume><elocation-id>306</elocation-id><pub-id pub-id-type="doi">10.3390/ph15030306</pub-id><pub-id pub-id-type="pmid">35337105</pub-id><pub-id pub-id-type="pmcid">PMC8949415</pub-id></element-citation></ref><ref id="B87-nanomaterials-15-01326"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pathan</surname><given-names>I.B.</given-names></name><name name-style="western"><surname>Jaware</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Shelke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ambekar</surname><given-names>W.</given-names></name></person-group><article-title>Curcumin Loaded Ethosomes for Transdermal Application: Formulation, Optimization, In-Vitro and In-Vivo Study</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2018</year><volume>44</volume><fpage>49</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.jddst.2017.11.005</pub-id></element-citation></ref><ref id="B88-nanomaterials-15-01326"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name></person-group><article-title>Hydrophobically Modified Inulin Based Nanoemulsions for Enhanced Stability and Transdermal Delivery of Retinyl Propionate</article-title><source>Colloids Surf. A Physicochem. Eng. Asp.</source><year>2022</year><volume>653</volume><fpage>129883</fpage><pub-id pub-id-type="doi">10.1016/j.colsurfa.2022.129883</pub-id></element-citation></ref><ref id="B89-nanomaterials-15-01326"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Madan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name></person-group><article-title>Quality by Design Approach for Formulation, Evaluation and Statistical Optimization of Diclofenac-Loaded Ethosomes via Transdermal Route</article-title><source>Pharm. Dev. Technol.</source><year>2015</year><volume>20</volume><fpage>473</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.3109/10837450.2014.882939</pub-id><pub-id pub-id-type="pmid">24490793</pub-id></element-citation></ref><ref id="B90-nanomaterials-15-01326"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zagalo</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>B.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sim&#245;es</surname><given-names>S.</given-names></name></person-group><article-title>A Quality by Design (QbD) Approach in Pharmaceutical Development of Lipid-Based Nanosystems: A Systematic Review</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2022</year><volume>70</volume><fpage>103207</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2022.103207</pub-id></element-citation></ref><ref id="B91-nanomaterials-15-01326"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>S.C.C.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Pais</surname><given-names>A.A.C.C.</given-names></name><name name-style="western"><surname>Vitorino</surname><given-names>C.</given-names></name></person-group><article-title>Expanding Transdermal Delivery with Lipid Nanoparticles: A New Drug-in-NLC-in-Adhesive Design</article-title><source>Mol. Pharm.</source><year>2017</year><volume>14</volume><fpage>2099</fpage><lpage>2115</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b00211</pub-id><pub-id pub-id-type="pmid">28475834</pub-id></element-citation></ref><ref id="B92-nanomaterials-15-01326"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arora</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nanda</surname><given-names>S.</given-names></name></person-group><article-title>Quality by Design Driven Development of Resveratrol Loaded Ethosomal Hydrogel for Improved Dermatological Benefits via Enhanced Skin Permeation and Retention</article-title><source>Int. J. Pharm.</source><year>2019</year><volume>567</volume><fpage>118448</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.118448</pub-id><pub-id pub-id-type="pmid">31226472</pub-id></element-citation></ref><ref id="B93-nanomaterials-15-01326"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivadasan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Madkhali</surname><given-names>O.A.</given-names></name></person-group><article-title>The Design Features, Quality by Design Approach, Characterization, Therapeutic Applications, and Clinical Considerations of Transdermal Drug Delivery Systems&#8212;A Comprehensive Review</article-title><source>Pharmaceuticals</source><year>2024</year><volume>17</volume><elocation-id>1346</elocation-id><pub-id pub-id-type="doi">10.3390/ph17101346</pub-id><pub-id pub-id-type="pmid">39458987</pub-id><pub-id pub-id-type="pmcid">PMC11510585</pub-id></element-citation></ref><ref id="B94-nanomaterials-15-01326"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>P.</given-names></name><name name-style="western"><surname>Muskan</surname></name><name name-style="western"><surname>Kriplani</surname><given-names>P.</given-names></name></person-group><article-title>Quality by Design for Niosome-Based Nanocarriers to Improve Transdermal Drug Delivery from Lab to Industry</article-title><source>Int. J. Pharm.</source><year>2024</year><volume>666</volume><fpage>124747</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2024.124747</pub-id><pub-id pub-id-type="pmid">39326474</pub-id></element-citation></ref><ref id="B95-nanomaterials-15-01326"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name></person-group><article-title>Advance and Challenges in the Treatment of Skin Diseases with the Transdermal Drug Delivery System</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>2165</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15082165</pub-id><pub-id pub-id-type="pmid">37631379</pub-id><pub-id pub-id-type="pmcid">PMC10458513</pub-id></element-citation></ref><ref id="B96-nanomaterials-15-01326"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Musazzi</surname><given-names>U.M.</given-names></name><name name-style="western"><surname>Campani</surname><given-names>V.</given-names></name><name name-style="western"><surname>Biondi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Franz&#233;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>F.</given-names></name><name name-style="western"><surname>De Rosa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sinico</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cilurzo</surname><given-names>F.</given-names></name></person-group><article-title>Design and Development of Topical Liposomal Formulations in a Regulatory Perspective</article-title><source>Drug Deliv. Transl. Res.</source><year>2022</year><volume>12</volume><fpage>1811</fpage><lpage>1828</lpage><pub-id pub-id-type="doi">10.1007/s13346-021-01089-z</pub-id><pub-id pub-id-type="pmid">34755281</pub-id><pub-id pub-id-type="pmcid">PMC8577404</pub-id></element-citation></ref><ref id="B97-nanomaterials-15-01326"><label>97.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Food and Drug Administration (FDA)</collab></person-group><source>Drug Products, Including Biological Products, That Contain Nanomaterials&#8212;Guidance for Industry</source><publisher-name>FDA</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2017</year></element-citation></ref><ref id="B98-nanomaterials-15-01326"><label>98.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>European Medicines Agency (EMA)</collab></person-group><source>Reflection Paper on Surface Coating: General Issues for Consideration Regarding Parenteral Administration of Coated Nanomedicine Products</source><publisher-name>EMA</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2013</year></element-citation></ref><ref id="B99-nanomaterials-15-01326"><label>99.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>European Medicine Agency (EMA)</collab></person-group><source>Reflection Paper on the Data Requirements for Intravenous Liposomal Products Developed with Reference to an Innovator Liposomal Product</source><publisher-name>EMA</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2013</year></element-citation></ref><ref id="B100-nanomaterials-15-01326"><label>100.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Food and Drug Administration (FDA)</collab></person-group><source>Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability, and Labeling Documentation Guidance for Industry</source><publisher-name>FDA</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2018</year></element-citation></ref><ref id="B101-nanomaterials-15-01326"><label>101.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>European Medicines Agency (EMA)</collab></person-group><source>Draft Guideline on Quality and Equivalence of Topical Products</source><publisher-name>EMA</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2018</year></element-citation></ref><ref id="B102-nanomaterials-15-01326"><label>102.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Food and Drug Administration (FDA)</collab></person-group><source>Transdermal and Topical Delivery Systems&#8212;Product Development and Quality Considerations</source><publisher-name>FDA</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2019</year></element-citation></ref></ref-list></back><floats-group><fig position="float" id="nanomaterials-15-01326-f001" orientation="portrait"><label>Figure 1</label><caption><p>Schematic illustration of the skin layer showing penetration routes of the drug administered through the skin [<xref rid="B15-nanomaterials-15-01326" ref-type="bibr">15</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nanomaterials-15-01326-g001.jpg"/></fig><fig position="float" id="nanomaterials-15-01326-f002" orientation="portrait"><label>Figure 2</label><caption><p>Schematic representation of an SLN and a NLC sterically stabilized with a neutral surfactant (gray) [<xref rid="B59-nanomaterials-15-01326" ref-type="bibr">59</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nanomaterials-15-01326-g002.jpg"/></fig><fig position="float" id="nanomaterials-15-01326-f003" orientation="portrait"><label>Figure 3</label><caption><p>Morphological models of different types of nanostructured lipid carriers (NLCs) [<xref rid="B42-nanomaterials-15-01326" ref-type="bibr">42</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nanomaterials-15-01326-g003.jpg"/></fig><fig position="float" id="nanomaterials-15-01326-f004" orientation="portrait"><label>Figure 4</label><caption><p>Schematic representation of the different types of lipid-based vesicular delivery systems [<xref rid="B22-nanomaterials-15-01326" ref-type="bibr">22</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nanomaterials-15-01326-g004.jpg"/></fig><fig position="float" id="nanomaterials-15-01326-f005" orientation="portrait"><label>Figure 5</label><caption><p>A schematic representation of the main permeation mechanisms of ethosomes: (<bold>A</bold>) the ethanol effect and (<bold>B</bold>) the ethosome effect [<xref rid="B67-nanomaterials-15-01326" ref-type="bibr">67</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nanomaterials-15-01326-g005.jpg"/></fig><fig position="float" id="nanomaterials-15-01326-f006" orientation="portrait"><label>Figure 6</label><caption><p>A schematic representation of the advantages of the lipid-based drug delivery transdermal systems.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nanomaterials-15-01326-g006.jpg"/></fig><fig position="float" id="nanomaterials-15-01326-f007" orientation="portrait"><label>Figure 7</label><caption><p>The QbD approach towards the design and development of the lipid-based drug delivery transdermal systems.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nanomaterials-15-01326-g007.jpg"/></fig><fig position="float" id="nanomaterials-15-01326-f008" orientation="portrait"><label>Figure 8</label><caption><p>Ishikawa diagram presenting the CQAs and CPPs for lipid-based drug delivery transdermal systems.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nanomaterials-15-01326-g008.jpg"/></fig><table-wrap position="float" id="nanomaterials-15-01326-t001" orientation="portrait"><object-id pub-id-type="pii">nanomaterials-15-01326-t001_Table 1</object-id><label>Table 1</label><caption><p>A synopsis of the main lipid-based drug delivery systems for transdermal administration and their properties.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vesicular Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Physicochemical<break/>Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">API</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Application</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Key Findings</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Liposomes</td><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 600&#8211;900 nm (MLVs) and 300&#8211;600 nm (ULVs)</p></list-item><list-item><p><bold>EE%</bold>: 40&#8211;95% (MLVs) and 20&#8211;60% (ULVs)</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Avanafil</td><td align="center" valign="middle" rowspan="1" colspan="1">Erectile dysfunction</td><td align="center" valign="middle" rowspan="1" colspan="1">Four-fold increase in permeation and seven-fold in bioavailability compared to the conventional suspensions</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B33-nanomaterials-15-01326" ref-type="bibr">33</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 100&#8211;150 nm</p></list-item><list-item><p><bold>EE%</bold>: 85%</p></list-item><list-item><p><bold>PDI</bold>: 0.1&#8211;0.3</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Vitamin D3</td><td align="center" valign="middle" rowspan="1" colspan="1">UV-protective, antiaging, and regenerative agents</td><td align="center" valign="middle" rowspan="1" colspan="1">Increased retention of Vitamin D3 in skin; improved skin appearance</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B34-nanomaterials-15-01326" ref-type="bibr">34</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 120 </p></list-item><list-item><p><bold>EE%</bold>: 10%</p></list-item><list-item><p><bold>PDI</bold>: 0.3</p></list-item><list-item><p><bold>Zeta potential</bold>: &#8722;27 mV</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Folic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">UV-protective, antiaging, and regenerative agents</td><td align="center" valign="middle" rowspan="1" colspan="1">Liposome stabilization at room temperature; transdermal penetration enhancement</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B35-nanomaterials-15-01326" ref-type="bibr">35</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 80&#8211;100 nm</p></list-item><list-item><p><bold>EE%</bold>: 60&#8211;95% (CBD) and 50&#8211;90% (LD)</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lidocaine (LD)/cannabidiol (CBD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain relief</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improved skin penetration; 1-year storage stability</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-nanomaterials-15-01326" ref-type="bibr">36</xref>]</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Solid Lipid Nanoparticles (SLNs)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 60&#8211;100 nm</p></list-item><list-item><p><bold>EE%</bold>: 40&#8211;80% (cyclosporine A) and 80&#8211;100% (calcipotriol)</p></list-item><list-item><p><bold>PDI</bold>: 0.2</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyclosporine A and calcipotriol</td><td align="center" valign="middle" rowspan="1" colspan="1">Psoriasis and inflammation treatment</td><td align="center" valign="middle" rowspan="1" colspan="1">Low scores of eye inflammation and psoriatic symptoms</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B15-nanomaterials-15-01326" ref-type="bibr">15</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 204 nm</p></list-item><list-item><p><bold>EE%</bold>: 33%</p></list-item><list-item><p><bold>PDI</bold>: 0.6</p></list-item><list-item><p><bold>Zeta potential</bold>: &#8722;5 mV</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Metformin</td><td align="center" valign="middle" rowspan="1" colspan="1">Topical anti-inflammatory</td><td align="center" valign="middle" rowspan="1" colspan="1">Enhanced penetration to deeper skin layers</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B37-nanomaterials-15-01326" ref-type="bibr">37</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 111&#8211;416 nm</p></list-item><list-item><p><bold>EE%</bold>: 73&#8211;94%</p></list-item><list-item><p><bold>PDI</bold>: 0.1&#8211;0.3</p></list-item><list-item><p><bold>Zeta potential</bold>: &#8722;5 to &#8722;23 mV</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Amphotericin B</td><td align="center" valign="middle" rowspan="1" colspan="1">Antifungal therapy</td><td align="center" valign="middle" rowspan="1" colspan="1">Enhanced efficacy and reduced adverse events</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B38-nanomaterials-15-01326" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 363&#8211;423 nm</p></list-item><list-item><p><bold>PDI</bold>: 0.4&#8211;0.5</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Eugenol</td><td align="center" valign="middle" rowspan="1" colspan="1">Antifungal therapy</td><td align="center" valign="middle" rowspan="1" colspan="1">Enhanced efficacy and reduced adverse events</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B39-nanomaterials-15-01326" ref-type="bibr">39</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 179&#8211;279 nm</p></list-item><list-item><p><bold>EE%</bold>: 54&#8211;76%</p></list-item><list-item><p><bold>PDI</bold>: 0.2&#8211;0.3</p></list-item><list-item><p><bold>Zeta potential</bold>: &#8722;23 to &#8722;34 mV</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Fluconazole</td><td align="center" valign="middle" rowspan="1" colspan="1">Antifungal therapy</td><td align="center" valign="middle" rowspan="1" colspan="1">Enhanced efficacy and reduced adverse events</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 128 nm</p></list-item><list-item><p><bold>EE%</bold>: 88%</p></list-item><list-item><p><bold>PDI</bold>: 0.3</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Sesamol</td><td align="center" valign="middle" rowspan="1" colspan="1">Antioxidant activity for thetreatment of skin cancer</td><td align="center" valign="middle" rowspan="1" colspan="1">Enhanced bioavailability up to the desired anticancer effect</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B40-nanomaterials-15-01326" ref-type="bibr">40</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 139 nm</p></list-item><list-item><p><bold>EE%</bold>: 91%</p></list-item><list-item><p><bold>PDI</bold>: 0.3</p></list-item><list-item><p><bold>Zeta potential</bold>: &#8722;30 mV</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Silybin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antioxidant activity against irritant contact dermatitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhanced skin delivery and therapeutic efficacy in treating irritant contact dermatitis compared to conventional formulations</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-nanomaterials-15-01326" ref-type="bibr">41</xref>]</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Nanostructured Lipid Carriers (NLCs)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 260&#8211;320 nm</p></list-item><list-item><p><bold>PDI</bold>: 0.3</p></list-item><list-item><p><bold>Zeta potential</bold>: &#8722;42 to &#8722;45 mV</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Calcipotriol and methotrexate</td><td align="center" valign="middle" rowspan="1" colspan="1">Psoriasis treatment</td><td align="center" valign="middle" rowspan="1" colspan="1">Enhanced skin permeation and negligible irritation</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B42-nanomaterials-15-01326" ref-type="bibr">42</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 150&#8211;300 nm</p></list-item><list-item><p><bold>EE%</bold>: 55&#8211;65%</p></list-item><list-item><p><bold>PDI</bold>: &lt;0.2</p></list-item><list-item><p><bold>Zeta potential</bold>: &#8722;30 to &#8722;35 mV</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Acitretin</td><td align="center" valign="middle" rowspan="1" colspan="1">Psoriasis treatment</td><td align="center" valign="middle" rowspan="1" colspan="1">Improved therapeutic response (reduced erythema) with mild adverse effects versus commercial gel</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B43-nanomaterials-15-01326" ref-type="bibr">43</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 214 nm</p></list-item><list-item><p><bold>EE%</bold>: 93%</p></list-item><list-item><p><bold>PDI</bold>: 0.2</p></list-item><list-item><p><bold>Zeta potential</bold>: &#8722;31 mV</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Flurbiprofen</td><td align="center" valign="middle" rowspan="1" colspan="1">Treatment of osteoarthritis, rheumatoidarthritis</td><td align="center" valign="middle" rowspan="1" colspan="1">Reduction in erythema along with maintenance of the anti-inflammatory effect versus the commercial gel</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B44-nanomaterials-15-01326" ref-type="bibr">44</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 218 nm</p></list-item><list-item><p><bold>EE%</bold>: 65%</p></list-item><list-item><p><bold>PDI</bold>: 0.3</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Difluctolone valerate</td><td align="center" valign="middle" rowspan="1" colspan="1">Treatment of skin diseases such as psoriasis,<break/>acne, tinea, ulcers, and discoid lupus erythematosus</td><td align="center" valign="middle" rowspan="1" colspan="1">High targeting of the API in the stratum corneum (SC) and limited systemic side effects versus Nerisone<sup>&#174;</sup> cream</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B45-nanomaterials-15-01326" ref-type="bibr">45</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 173 nm</p></list-item><list-item><p><bold>EE%</bold>: 90%</p></list-item><list-item><p><bold>PDI</bold>: 0.3</p></list-item><list-item><p><bold>Zeta potential</bold>: &#8722;57 mV</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Luliconazole</td><td align="center" valign="middle" rowspan="1" colspan="1">Antifungal therapy</td><td align="center" valign="middle" rowspan="1" colspan="1">Enhanced antifungal activity with no irritation compared to the commercial formulation</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B46-nanomaterials-15-01326" ref-type="bibr">46</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 170&#8211;240 nm</p></list-item><list-item><p><bold>EE%</bold>: 99%</p></list-item><list-item><p><bold>PDI</bold>: 0.3</p></list-item><list-item><p><bold>Zeta potential</bold>: &#8722;40 to &#8722;55 mV</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Donepezil</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alzheimer disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Higher skin permeation with limited adverse effects</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B47-nanomaterials-15-01326" ref-type="bibr">47</xref>]</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ethosomes</td><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 120&#8211;150 nm</p></list-item><list-item><p><bold>EE%</bold>: 85&#8211;95%</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Psoralen</td><td align="center" valign="middle" rowspan="1" colspan="1">Psoriasis treatment</td><td align="center" valign="middle" rowspan="1" colspan="1">6.56&#215; higher deposition vs. control</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B48-nanomaterials-15-01326" ref-type="bibr">48</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 143 nm</p></list-item><list-item><p><bold>EE%</bold>: 69%</p></list-item><list-item><p><bold>PDI</bold>: 0.1</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Methotrexate</td><td align="center" valign="middle" rowspan="1" colspan="1">Psoriasis and cancer therapy</td><td align="center" valign="middle" rowspan="1" colspan="1">Improved efficacy, lower toxicity</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B49-nanomaterials-15-01326" ref-type="bibr">49</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 123 nm</p></list-item><list-item><p><bold>EE%</bold>: 79%</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Erythromycin</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-bacterial treatment </td><td align="center" valign="middle" rowspan="1" colspan="1">Significantly improved anti-bacterial action vs. free drug in in vitro tests; non-toxic to dermal cultured fibroblasts</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B50-nanomaterials-15-01326" ref-type="bibr">50</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 120 nm</p></list-item><list-item><p><bold>EE%</bold>: 80&#8211;90%</p></list-item><list-item><p><bold>Zeta potential</bold>: +20 mV</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Acyclovir</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-viral treatment</td><td align="center" valign="middle" rowspan="1" colspan="1">Enhanced permeability of ethosome formulations</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B51-nanomaterials-15-01326" ref-type="bibr">51</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 79 nm</p></list-item><list-item><p><bold>EE%</bold>: 86% </p></list-item><list-item><p><bold>PDI</bold>: 0.1</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ligustrazine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pulmonary treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AUC 2.09-fold increase vs. oral; 209% relative bioavailability</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-nanomaterials-15-01326" ref-type="bibr">52</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Transfersomes</td><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 100&#8211;200 nm</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Triamcinolone acetonide</td><td align="center" valign="middle" rowspan="1" colspan="1">Corticosteroid</td><td align="center" valign="middle" rowspan="1" colspan="1">25&#215; lower dose for same efficacy</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B53-nanomaterials-15-01326" ref-type="bibr">53</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p><bold>Particle size</bold>: 90&#8211;200 nm</p></list-item><list-item><p><bold>EE%</bold>: 60&#8211;90%</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Dexamethasone</td><td align="center" valign="middle" rowspan="1" colspan="1">Corticosteroid</td><td align="center" valign="middle" rowspan="1" colspan="1">Improved transdermal delivery, prolonged release with no lag time</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B54-nanomaterials-15-01326" ref-type="bibr">54</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">No data available due to patent restrictions</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insulin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diabetes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Comparable levels to subcutaneous injections</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B55-nanomaterials-15-01326" ref-type="bibr">55</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="nanomaterials-15-01326-t002" orientation="portrait"><object-id pub-id-type="pii">nanomaterials-15-01326-t002_Table 2</object-id><label>Table 2</label><caption><p>The clinical status of lipid-based drug delivery systems for transdermal administration.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Lipid-Based <break/>Formulation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">API</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Indication</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Added Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Status</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Liposomes + microneedles</td><td align="center" valign="middle" rowspan="1" colspan="1">Insulin</td><td align="center" valign="middle" rowspan="1" colspan="1">Diabetes</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Preclinical studies</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B75-nanomaterials-15-01326" ref-type="bibr">75</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SLNs</td><td align="center" valign="middle" rowspan="1" colspan="1">Lidocaine</td><td align="center" valign="middle" rowspan="1" colspan="1">Local anesthesia</td><td align="center" valign="middle" rowspan="1" colspan="1">Longer local anesthesia </td><td align="center" valign="middle" rowspan="1" colspan="1">Preclinical studies</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B74-nanomaterials-15-01326" ref-type="bibr">74</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Transfersomes</td><td align="center" valign="middle" rowspan="1" colspan="1">Diclofenac</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-inflammatory</td><td align="center" valign="middle" rowspan="1" colspan="1">Increased tissue concentration and permeation</td><td align="center" valign="middle" rowspan="1" colspan="1">Clinical study</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B71-nanomaterials-15-01326" ref-type="bibr">71</xref>,<xref rid="B72-nanomaterials-15-01326" ref-type="bibr">72</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NLCs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Estradiol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hormone therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.5% symptom relief, hormone normalization</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B73-nanomaterials-15-01326" ref-type="bibr">73</xref>]</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>